amantadine has been researched along with Parkinson Disease in 640 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need." | 9.24 | ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. ( Agarwal, P; Hauser, RA; Hull, KL; Isaacson, SH; Johnson, R; Lyons, KE; Nausieda, PA; Pahwa, R; Stempien, MJ; Tanner, CM; Truong, DD, 2017) |
| "The AMANDYSK trial was designed to assess long-term efficacy of chronic treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced dyskinesia (LID)." | 9.19 | Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. ( Azulay, JP; Bonnet, AM; Brefel-Courbon, C; Corvol, JC; Damier, P; Dellapina, E; Destée, A; Durif, F; Galitzky, M; Lebouvier, T; Meissner, W; Ory-Magne, F; Rascol, O; Salis, A; Sommet, A; Thalamas, C; Tison, F; Viallet, F; Vidailhet, M, 2014) |
| "To investigate the possible efficacy of amantadine in the control of pathological gambling (PG) associated with Parkinson disease (PD), 17 PD patients with PG were randomly selected for a double-blind crossover study with amantadine 200mg/day versus placebo and an open follow-up." | 9.14 | Pathological gambling in Parkinson disease is reduced by amantadine. ( Bonanni, L; Di Iorio, A; Gambi, F; Onofrj, M; Thomas, A, 2010) |
| "An aim of a study was to establish the relationship between pain, motor complications and depression in Parkinson's disease and evaluate an effect of the 3 months therapy with the dopamine receptor agonist pramipexole (mirapex)." | 9.13 | [Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole]. ( Letvinenko, IV; Mogil'naia, VI; Odinak, MM, 2008) |
| "Amantadine increases the risk of corneal edema in a dose-dependent manner." | 7.83 | Amantadine Use as a Risk Factor for Corneal Edema: A Nationwide Cohort Study in Taiwan. ( Chang, CH; Cheng, KC; Hsu, SL; Lee, PY; Lin, CC; Lin, CP; Tu, HP, 2016) |
| "A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD)." | 7.76 | Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. ( Lang, AE; Potenza, MN; Siderowf, AD; Sohr, M; Stacy, M; Voon, V; Weintraub, D; Whetteckey, J; Wunderlich, GR, 2010) |
| "The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group)." | 7.73 | Association between amantadine and the onset of dementia in Parkinson's disease. ( Bonuccelli, U; Ceravolo, R; Inzelberg, R; Klein, C; Logi, C; Miniowich, A; Rabey, JM; Rossi, C; Schechtman, E; Strugatsky, R, 2006) |
| "We present three patients who, after long-term therapy with amantadine (4 to 18 years), experienced an acute delirium with confusion, disorientation, agitation, and paranoia on withdrawal." | 7.70 | Acute delirium after withdrawal of amantadine in Parkinson's disease. ( Brown, DL; Factor, SA; Molho, ES, 1998) |
| "In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy." | 7.65 | Visual hallucinations and delirium during treatment with amantadine (Symmetrel). ( Postma, JU; Van Tilburg, W, 1975) |
| "Amantadine was originally introduced and utilized as an antiviral medication." | 6.48 | Amantadine: the journey from fighting flu to treating Parkinson disease. ( Haider, M; Hubsher, G; Okun, MS, 2012) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 5.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "Corneal edema is a known but unusual side effect of amantadine therapy, rarely reported in the neurological literature." | 5.37 | Amantadine induced reversible corneal edema. ( Deogaonkar, M; Vitek, J; Wilson, K, 2011) |
| "Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need." | 5.24 | ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. ( Agarwal, P; Hauser, RA; Hull, KL; Isaacson, SH; Johnson, R; Lyons, KE; Nausieda, PA; Pahwa, R; Stempien, MJ; Tanner, CM; Truong, DD, 2017) |
| "The AMANDYSK trial was designed to assess long-term efficacy of chronic treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced dyskinesia (LID)." | 5.19 | Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. ( Azulay, JP; Bonnet, AM; Brefel-Courbon, C; Corvol, JC; Damier, P; Dellapina, E; Destée, A; Durif, F; Galitzky, M; Lebouvier, T; Meissner, W; Ory-Magne, F; Rascol, O; Salis, A; Sommet, A; Thalamas, C; Tison, F; Viallet, F; Vidailhet, M, 2014) |
| "To investigate the possible efficacy of amantadine in the control of pathological gambling (PG) associated with Parkinson disease (PD), 17 PD patients with PG were randomly selected for a double-blind crossover study with amantadine 200mg/day versus placebo and an open follow-up." | 5.14 | Pathological gambling in Parkinson disease is reduced by amantadine. ( Bonanni, L; Di Iorio, A; Gambi, F; Onofrj, M; Thomas, A, 2010) |
| "An aim of a study was to establish the relationship between pain, motor complications and depression in Parkinson's disease and evaluate an effect of the 3 months therapy with the dopamine receptor agonist pramipexole (mirapex)." | 5.13 | [Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole]. ( Letvinenko, IV; Mogil'naia, VI; Odinak, MM, 2008) |
| "We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the alpha-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis)." | 5.11 | Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series. ( Gonzalez, MA; Lieberman, A; Papapetropoulos, S; Roberts, EL; Singer, C, 2005) |
| "We report a case of a man with spinocerebellar ataxia (SCA) on high-dose amantadine who was admitted for acute on chronic dysphagia secondary to progression of SCA." | 4.31 | Amantadine withdrawal in a patient with spinocerebellar ataxia. ( Chang, E; Pak, A, 2023) |
| "To report a case of a patient showing bilateral corneal opacities after amantadine chronic treatment for Parkinson's Disease (PD) and corneal edema associated with intra-epithelial and -endothelial depositions." | 4.12 | Amantadine therapy for Parkinson's Disease: In Vivo Confocal Microscopy corneal findings, case report and revision of literature. ( Cennamo, M; Dragotto, F; Favuzza, E; Mencucci, R; Morelli, A, 2022) |
| "To evaluate the progression of corneal endothelial changes in patients with Parkinson disease (PD) on long-term oral amantadine therapy." | 3.91 | Corneal Evaluation in Patients With Parkinsonism on Long-Term Amantadine Therapy. ( Daggumilli, S; Ganger, A; Goyal, V; Tandon, R; Vanathi, M, 2019) |
| "Amantadine increases the risk of corneal edema in a dose-dependent manner." | 3.83 | Amantadine Use as a Risk Factor for Corneal Edema: A Nationwide Cohort Study in Taiwan. ( Chang, CH; Cheng, KC; Hsu, SL; Lee, PY; Lin, CC; Lin, CP; Tu, HP, 2016) |
| "After chronic levodopa use, many patients with Parkinson disease (PD) develop involuntary movements." | 3.80 | Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism? ( Lewitt, PA; Mouradian, MM, 2014) |
| "A 64 year-old female with Parkinson disease treated with amantadine for two years who suddenly suffered bilateral corneal oedema." | 3.78 | [Corneal toxicity due to amantadine]. ( Avendaño-Cantos, EM; Celis-Sánchez, J; Gálvez-Martínez, J; González Del Valle, F; López-Arroquia, E; Mesa-Varona, D, 2012) |
| "A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD)." | 3.76 | Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. ( Lang, AE; Potenza, MN; Siderowf, AD; Sohr, M; Stacy, M; Voon, V; Weintraub, D; Whetteckey, J; Wunderlich, GR, 2010) |
| "We report a fatal intoxication in a 59-year-old woman who had uremia undergoing hemodialysis, and then took amantadine and pramipexole for Parkinsonian tremor." | 3.74 | Fatal intoxication using amantadine and pramipexole in a uremic patient. ( Hong, CT; Lu, CJ; Sun, Y, 2008) |
| "To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long-term amantadine." | 3.74 | Corneal endothelial dysfunction associated with amantadine toxicity. ( Chang, KC; Kim, MK; Lee, JH; Wee, WR, 2008) |
| "In the last several years, amantadine has been increasingly prescribed for akinesia in Parkinson's disease and to combat fatigue associated with multiple sclerosis." | 3.73 | Amantadine-induced livedo reticularis: a report of two cases. ( Cook-Norris, RH; Hayes, BB; Miller, JL; Rodriguez, A; Zic, JA, 2006) |
| "The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group)." | 3.73 | Association between amantadine and the onset of dementia in Parkinson's disease. ( Bonuccelli, U; Ceravolo, R; Inzelberg, R; Klein, C; Logi, C; Miniowich, A; Rabey, JM; Rossi, C; Schechtman, E; Strugatsky, R, 2006) |
| "We present three patients who, after long-term therapy with amantadine (4 to 18 years), experienced an acute delirium with confusion, disorientation, agitation, and paranoia on withdrawal." | 3.70 | Acute delirium after withdrawal of amantadine in Parkinson's disease. ( Brown, DL; Factor, SA; Molho, ES, 1998) |
| "The relative efficacy of trihexiphenidyl hydrochloride, amantadine hydrochloride, and low-dose carbidopa-levodopa in reducing parkinsonian tremor was investigated using objective techniques." | 3.67 | Pharmacologic treatment of parkinsonian tremor. ( Koller, WC, 1986) |
| "In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy." | 3.65 | Visual hallucinations and delirium during treatment with amantadine (Symmetrel). ( Postma, JU; Van Tilburg, W, 1975) |
| "We have studied the urinary excretion of 1,4-methylhistamine (1,4-MeHm), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in patients with Parkinson's disease, choreiform movements and essential tremor." | 3.65 | Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. ( Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ, 1977) |
| "Amantadine is an antiviral drug available in oral and intravenous forms." | 2.90 | Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study. ( Djaldetti, R; Khlebtovsky, A; Steiner, I; Treves, T, 2019) |
| " ADS-5102 is an extended release amantadine capsule formulation, designed for once-daily dosing at bedtime (qhs) to provide high concentrations upon waking and throughout the day, with lower concentrations in the evening." | 2.90 | Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. ( Hauser, RA; Johnson, R; McClure, N; Nguyen, JT; Pahwa, R; Patni, R; Souza-Prien, CJ; Wargin, WA; Went, GT, 2019) |
| "In Parkinson's disease, dyskinesias result from disease progression and chronic levodopa therapy." | 2.90 | Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials. ( Deik, A; Isaacson, S; Jimenez-Shaheed, J; Johnson, R; Malaty, IA; Pahwa, R; Patni, R, 2019) |
| "Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson's disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia." | 2.87 | Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease. ( Criswell, SR; Elmer, LW; Felt, L; Johnson, R; Juncos, JL; Parashos, S; Patni, R; Singer, C; Truong, DD, 2018) |
| "The treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy." | 2.84 | Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). ( Azulay, JP; Eggert, K; Ehret, R; Felt, L; Hauser, RA; Isaacson, S; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM; Trenkwalder, C, 2017) |
| "Amantadine is an old, antiviral compound, which moderately improves motor behavior in Parkinson's disease." | 2.82 | GOCOVRI ( Müller, T, 2022) |
| "In advanced Parkinson's disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS)." | 2.78 | Amantadine improves gait in PD patients with STN stimulation. ( Chan, HF; Kukkle, PL; Lim, SY; Merello, M; Moro, E; Poon, YY, 2013) |
| "Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability." | 2.78 | Which dyskinesia scale best detects treatment response? ( Chung, KA; Ge, S; Goetz, CG; Hauser, RA; Jaglin, JA; Miyasaki, JM; Nicholas, AP; Nutt, JG; Poewe, W; Rascol, O; Seppi, K; Stacy, MA; Stebbins, GT; Tanner, CM; Urkowitz, A, 2013) |
| "Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease." | 2.75 | Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. ( Hisanaga, K; Kawamura, T; Kuno, S; Nomoto, M; Oeda, T; Sawada, H; Yamamoto, K; Yamamoto, M, 2010) |
| "Levodopa was discontinued for 3 days and during that time amantadine sulfate intravenous was administrated." | 2.73 | Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease. ( Friedman, A; Koziorowski, D, 2007) |
| "Amantadine was first reported effective in the treatment of Parkinson's disease in 1969 and several studies were published in the 1970s supporting its efficacy." | 2.72 | Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease? ( Feldman, M; Margolesky, J; Marmol, S; Singer, C, 2021) |
| "Amantadine was reduced to 50mg daily for 4 days and then discontinued." | 2.72 | Amantadine Associated Myoclonus: Case Report and Review of the Literature. ( Lee, AJ; Poon, LH; Vuong, M; Zuzuarregui, JR, 2021) |
| "Amantadine is an antiparkinsonian medication scarcely associated with PHS." | 2.72 | Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature. ( Dos Santos, DT; Imthon, AK; Pille, A; Schumacher-Schuh, AF; Strelow, MZ, 2021) |
| " Twenty-four drug-related adverse events were recorded of which four were regarded as serious." | 2.72 | Efficacy and safety of high-dose cabergoline in Parkinson's disease. ( Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G, 2006) |
| "300 mg amantadine reduces dyskinesia in Parkinson's disease by approximately 45% but the benefit lasted less than eight months." | 2.71 | Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. ( Armellino, K; Di Iorio, A; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A, 2004) |
| "Amantadine treatment significantly increased [(11)C-]Raclopride binding (caudate: 10% p = 0." | 2.70 | New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study. ( Carpinelli, A; Fazio, F; Franceschi, M; Galli, L; Gobbo, C; Messa, C; Moresco, RM; Panzacchi, A; Rizzo, G; Volonte, MA, 2002) |
| "amantadine was withdrawn in all patients." | 2.70 | Amantadine for dyskinesia in patients affected by severe Parkinson's disease. ( Onofrj, M; Paci, C; Thomas, A, 2001) |
| "Patients with Parkinson's disease were treated with different antiparkinsonian drugs and the amino acid levels in serum and cerebrospinal fluid were determined." | 2.65 | [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)]. ( Gerstenbrand, F; Gründig, E, 1980) |
| "Forty-two patients with Parkinson's disease were given amantadine HC1 (Symmetrel) and placebo in an 18 week double-blind cross-over study to determine if amantadine provided additional benefit when combined with levodopa and carbidopa (Sinemet)." | 2.64 | Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. ( Savery, F, 1977) |
| "Twenty-three patients with Parkinson's disease participated in long-term, double-blind evaluations of the effectiveness and side effects of amantadine in combination with levodopa therapy." | 2.64 | Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses. ( Fahn, S; Isgreen, WP, 1975) |
| " Dextroamphetamine in lower dosage also reduced disability by some 17 percent." | 2.64 | Amphetamines in the treatment of Parkinson's disease. ( Asselman, P; Bovill, KT; Marsden, CD; Parkes, JD; Phipps, JA; Rose, P; Tarsy, D, 1975) |
| "The further therapeutic benefit of piribedil when combined with amantadine or Levodopa was studied by a double-blind, cross-over trial in 15 patients with Parkinson's disease." | 2.64 | Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa. ( Callaghan, N; Fitzpatrick, E; O'Mahony, JB, 1975) |
| "Amantadine proved to be a useful and safe addition to the armamentarium when given in daily doses of 200 mg." | 2.64 | Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study. ( Barbeau, A; Botez, MI; Joubert, M; Mars, H, 1971) |
| "Amantadine ER has potential to supplement levodopa therapy in PD and improve patient therapeutic outcomes." | 2.61 | Extended-Release Amantadine for Levodopa-Induced Dyskinesia. ( Dashtipour, K; Lyons, KE; Pahwa, R; Tafreshi, AR, 2019) |
| "Levodopa has the best safety data for use in pregnancy and amantadine should be avoided in women who are pregnant or trying to become pregnant." | 2.55 | Parkinson's disease and pregnancy: An updated review. ( Hiller, A; Seier, M, 2017) |
| " While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require deep brain stimulation to control their troublesome motor fluctuations and LIDs." | 2.53 | Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. ( Jankovic, J; Vijayakumar, D, 2016) |
| " Staff familiarity with Parkinson disease, and especially carbidopa-levodopa dosing and dynamics, may prevent such problems and streamline hospital and nursing home care." | 2.50 | Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls. ( Ahlskog, JE, 2014) |
| "Amantadine was originally introduced and utilized as an antiviral medication." | 2.48 | Amantadine: the journey from fighting flu to treating Parkinson disease. ( Haider, M; Hubsher, G; Okun, MS, 2012) |
| "In the mid-1980s, the treatment of Parkinson's disease was quite exclusively centered on dopatherapy and was focusing on dopamine systems and motor symptoms." | 2.47 | Milestones in Parkinson's disease therapeutics. ( Lozano, A; Poewe, W; Rascol, O; Stern, M, 2011) |
| "Parkinson disease is a complex neurodegenerative disease with both motor and nonmotor symptoms." | 2.44 | Parkinson disease: managing a complex, progressive disease at all stages. ( Giroux, ML, 2007) |
| "ET tremor is usually characterized by symmetric bilateral postural and kinetic tremor, which may respond to low alcohol consumption." | 2.44 | [Diagnosis and treatment of tremor in Parkinson's disease and essential tremor]. ( Benecke, R; Wolters, A, 2007) |
| "The available pharmacotherapies for Parkinson's disease address symptomatology because no agent has been demonstrated to provide definite neuroprotection against the disease." | 2.44 | Pharmacotherapy for Parkinson's disease. ( Chen, JJ; Swope, DM, 2007) |
| "Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias." | 2.43 | Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. ( Goetz, CG; Poewe, W; Rascol, O; Sampaio, C, 2005) |
| " Wearing-off can be treated by dietary manipulation, shortening the dosing interval, substituting sustained-release levodopa, adding amantadine, or monoamine oxidase type B inhibitors, and other options, including catechol-O-methyltransferase inhibitors and the approved dopamine agonists addressed in another chapter." | 2.43 | Other pharmacological treatments for motor complications and dyskinesias. ( Waters, C, 2005) |
| "Abnormal involuntary movements known as dyskinesias are amongst the most disabling side-effects of levodopa therapy." | 2.42 | Amantadine for dyskinesia in Parkinson's disease. ( Clarke, CE; Crosby, NJ; Deane, KH, 2003) |
| "Amantadine has demonstrated both symptomatic benefit and dyskinesia benefit in some patients." | 2.42 | Rationale for current therapies in Parkinson's disease. ( Fernandez, HH; Okun, MS; Romrell, J, 2003) |
| "There are many causes of parkinsonism such as drug induced parkinsonism, subcortical vascular disease, and multisystem atrophy." | 2.42 | [Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?]. ( Ceballos-Baumann, A, 2003) |
| "Tremor-predominant Parkinson's disease is characterised by prominent tremor of one or more limbs with a relative lack of significant rigidity and bradykinesia." | 2.41 | Tremor-predominant Parkinson's disease. Approaches to treatment. ( Koller, W; Marjama-Lyons, J, 2000) |
| "The main pathophysiology of Parkinson's disease is neurodegeneration of nigrostriatal dopaminergic neurons." | 2.41 | [Pharmacological treatments of Parkinson's disease]. ( Iwata, S; Kaseda, S; Nomoto, M, 2001) |
| "Optimal management of Parkinson's disease patients requires careful titration of medications, with use of polypharmacy, including levodopa, dopamine agonists, catechol-O-methyltransferase inhibitors, amantadine, and anticholinergics in order to maintain good motor function and quality of life." | 2.41 | Parkinson's disease: medical treatment of moderate to advanced disease. ( Suchowersky, O, 2002) |
| "All major symptoms of Parkinson's disease, i." | 2.40 | [Treatment of Parkinson's disease with multiple drugs]. ( Kuno, S, 1997) |
| " Used as adjuvant treatment to levodopa, they help lowering the dosage of levodopa." | 2.40 | [Initial treatment of Parkinson's disease]. ( Kulisevsky, J; López-Villegas, D, 1997) |
| "Amantadine has been teratogenic in rats and selegiline has caused neurochemical and behavioral alterations in rats when coadministered with clorgyline." | 2.40 | Pregnancy in Parkinson's disease: a review of the literature and a case report. ( Hagell, P; Odin, P; Vinge, E, 1998) |
| "Two strategies of drug therapy for Parkinson's disease (PD) are neuroprotective and symptomatic." | 2.39 | Parkinson's disease: managing symptoms and preserving function. ( Sweeney, PJ, 1995) |
| "Other therapies in the early stages of Parkinson's disease may include neuroprotective agents, dopamine agonists, dopamine reuptake inhibitors, anticholinergics and/or amantadine." | 2.39 | Treatment options for early Parkinson's disease. ( Brownlee, HJ; Stacy, M, 1996) |
| "Amantadine has the best ratio of therapeutic effects to side effects when compared with the other anti-parkinsonian drugs currently used." | 2.39 | Twenty-five years of amantadine therapy in Parkinson's disease. ( Danielczyk, W, 1995) |
| "Amantadine has similar effects but is more active against rigidity and bradykinesia." | 2.39 | Early idiopathic parkinsonism: initiation and optimization of treatment. ( Calne, DB, 1994) |
| "Amantadine has been shown to be as effective as anticholinergics, but it lacks long-term efficacy." | 2.38 | Initiating treatment of Parkinson's disease. ( Koller, WC, 1992) |
| "The diagnosis and management of Parkinson's disease in the elderly is complicated by the common presence of multiple pathology and age related changes in drug handling." | 2.38 | Drug therapy for Parkinson's disease in the elderly. ( George, CF; Robertson, DR, 1990) |
| "The approach to treatment of Parkinson's disease depends on the severity of symptoms at presentation and the response to previous therapy." | 2.37 | Pharmacology of Parkinson's disease. ( Burton, K; Calne, DB, 1984) |
| "The drug treatment of Parkinson's disease has progressed through 3 main stages: firstly, the use of anticholinergic drugs and amantadine; then the introduction of levodopa and its association with peripheral decarboxylase inhibitors; and finally the use of direct acting dopamine agonist drugs." | 2.37 | Anti-parkinsonian drugs today. ( Quinn, NP, 1984) |
| "Amantadine is a drug with diverse uses ranging from prevention of influenza A illness to the treatment of patients with Parkinson's disease." | 2.37 | Clinical pharmacokinetics of amantadine hydrochloride. ( Aoki, FY; Sitar, DS, 1988) |
| "After the onset of Parkinson's disease, depression is very common." | 2.37 | Parkinson's disease in the elderly: psychiatric manifestations. ( Fonda, D, 1985) |
| "The treatment of Parkinson's disease today is complex, time-consuming, but rewarding." | 2.35 | Advances in the management of parkinson's disease. ( Marsden, CD, 1976) |
| "To compare the groups of Parkinson's Disease (PD) patients who were administered amantadine chronically and those who did not take this medication in the context of the incidence and severity of COVID-19 infection." | 1.91 | Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study. ( Dulski, J; Kasprzak, J; Koziorowski, D; Kwaśniak-Butowska, M; Przytuła, F; Roszmann, A; Schinwelski, M; Śmiłowska, K; Sołtan, W; Sławek, J, 2023) |
| "Amantadine use was associated with delayed LID onset in the 6- and 12-month landmark analyses, with adjusted hazard ratios of 0." | 1.72 | Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease. ( Lin, CH; Lin, FJ; Tai, CH; Wang, CC; Wu, RM; Wu, TL, 2022) |
| "Amantadine was initiated after a median of 7 years from PD diagnosis, and its prescription was correlated with the presence of dyskinesia (logistic regression odds ratio [OR] 3." | 1.56 | Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study. ( Damier, P; Delval, A; Derkinderen, P; Destée, A; Fabbri, M; Meissner, WG; Negre-Pages, L; Perez-Lloret, S; Rachdi, A; Rascol, O; Tison, F, 2020) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 1.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "Zonisamide is an antiepileptic drug developed in Japan, where its therapeutic effects on PD were also discovered and developed." | 1.51 | [Parkinson's Disease: amantadine, zonisamide, dabrafenib]. ( Okamoto, T, 2019) |
| "Amantadine is an old antiviral compound, which moderately improves impaired motor behaviour." | 1.51 | Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia. ( Möhr, JD; Müller, T, 2019) |
| "Metformin is a medication that is widely prescribed for the management of type 2 diabetes." | 1.48 | Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease. ( Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK, 2018) |
| " This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM." | 1.40 | Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat ( Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L, 2014) |
| "To investigate the association of illusions/hallucinations and plasma CRP levels in PD patients without symptomatic infections." | 1.40 | Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. ( Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K, 2014) |
| "The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease." | 1.39 | IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. ( Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N, 2013) |
| "Amantadine, a medication used in Parkinson's disease, has been known to cause LR localized to the lower, and to a rarer extent, the upper extremities." | 1.38 | Patient perception of Levido reticularis due to amantadine. ( Masroor, MS; Rana, AQ, 2012) |
| "Levodopa is the most effective medical treatment for Parkinson disease." | 1.38 | Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease. ( Tarsy, D, 2012) |
| "In patients who had impulse control disorders at baseline (n = 119), high dopamine agonist dose was associated with the presence of disorders at follow-up." | 1.38 | Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. ( Joutsa, J; Kaasinen, V; Martikainen, K; Vahlberg, T, 2012) |
| "Corneal edema is a known but unusual side effect of amantadine therapy, rarely reported in the neurological literature." | 1.37 | Amantadine induced reversible corneal edema. ( Deogaonkar, M; Vitek, J; Wilson, K, 2011) |
| " This case report serves as a reminder of the importance that patients receive their anti-Parkinsonian medications perioperatively, and highlights the potential benefits of inserting a gastric tube to continue anti-Parkinson's medication dosing during prolonged surgery." | 1.37 | Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence. ( Grice, T; Stagg, P, 2011) |
| "The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment." | 1.36 | The effect of amantadine on corneal endothelium in subjects with Parkinson's disease. ( Chang, KC; Jeon, BS; Jeong, JH; Kim, MK; Lee, JH; Wee, WR, 2010) |
| "Psychotic features in patients with Parkinson's Disease usually present as visual hallucinations against a background of cognitive deterioration and dopaminomimetic therapy." | 1.36 | Isolated delusional syndrome in Parkinson's Disease. ( Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N, 2010) |
| " We present the results of our own study on the effect of amantadine sulfate, prescribed in the dosage of 300 mg during 6 months, on cognitive disorders in 25 PD patients." | 1.36 | [The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease]. ( Bel'gusheva, ME; Fedorova, NV; Iablonskaia, AIu, 2010) |
| "We report a patient with Parkinson's disease who developed typical room tilt illusion." | 1.35 | Room tilt illusion in Parkinson's disease: loss of spatial reference frames? ( Hayashi, R; Katsumata, Y; Mimura, M; Yamaguchi, S, 2009) |
| "A 61-year-old man with Parkinson's disease (PD) developed sudden-onset visual impairment after initiation of amantadine treatment." | 1.35 | Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature. ( Ebihara, N; Hattori, N; Iwatake, A; Kubo, S; Murakami, A, 2008) |
| "We report a patient with Parkinson's disease presenting disabling punding, which was reversed by amantadine without aggravating motor function." | 1.35 | Amantadine may reverse punding in Parkinson's disease--observation in a patient. ( Imamura, T; Kashihara, K, 2008) |
| "Pergolide was increased to 8." | 1.33 | High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. ( Hundemer, HP; Oehlwein, C; Polzer, U; Schwarz, J; Storch, A; Trenkwalder, C; Winkelmann, J, 2005) |
| "Amantadine was therefore discontinued." | 1.33 | Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. ( Antico, J; Merello, M; Obeso, JA; Perez-Lloret, S, 2006) |
| "We describe an artist who depicted her visual hallucinations experienced in the course of Parkinson's disease." | 1.32 | An artist's view of drug-induced hallucinosis. ( Ebersbach, G, 2003) |
| "To assess the quality of life, the Parkinson's Disease Questionnaire (PDQ-39) was used." | 1.32 | Quality of life in Polish patients with long-lasting Parkinson's disease. ( Derejko, M; Friedman, A; Sławek, J; Zach, M, 2004) |
| "Motor complications and disease progression are responsible for devastating morbidity." | 1.32 | A young onset Parkinson's patient: a case study. ( Jung, SK, 2004) |
| "Amantadine was approved for treatment of Parkinson's disease in 1975, and for the influenza A virus infection in November 1998, in Japan." | 1.31 | [Incidence of amantadine-resistant influenza A (genotype Ser-31-Asn) in nursing homes in Niigata, Japan]. ( Kawasaki, S; Masuda, H; Oshitani, H; Saito, R; Sato, H; Suzuki, H, 2000) |
| "Treatment with amantadine should routinely be considered before indicating pallidotomy for levodopa-induced dyskinesias." | 1.31 | [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease]. ( Cersósimo, MG; Micheli, FE; Scorticati, MC, 2000) |
| "It is mainly related to disease progression and levodopa treatment." | 1.31 | Freezing of gait in patients with advanced Parkinson's disease. ( Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA, 2001) |
| "Amantadine has been proved to be beneficial in Parkinson's disease." | 1.31 | A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system. ( Carpinelli, A; Comi, G; Fazio, F; Gobbo, C; Messa, C; Moresco, RM; Rizzo, G; Volonté, MA, 2001) |
| "The treatment of Parkinson's disease unresponsive to dopaminergic substances and that associated with dementia remains problematical." | 1.31 | [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient]. ( Ceballos-Baumann, AO, 2002) |
| "We report 3 patients with Parkinson's disease and motor fluctuations who received high doses of pergolide without levodopa resulting in a reduction of motor fluctuations." | 1.30 | Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. ( Scheidtmann, K; Schwarz, J; Trenkwalder, C, 1997) |
| " In the statistical investigation by the multivariate analysis (quantification method type II), the age of initial levodopa therapy, the duration from the onset to the initiation of levodopa therapy, and the duration of levodopa therapy were not closely related to the development of any adverse reaction, while Hoehn & Yahr's stage and the dosage of levodopa had the most significant influence on the development of adverse reactions." | 1.30 | [Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease]. ( Endo, S; Hikiji, A; Nakamura, Y; Yoshinaga, J, 1997) |
| "Parkinson's disease is a chronic and disabling illness and there is currently wide variation in its management." | 1.30 | Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. ( Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Playfer, J; Sawle, GV; Schapira, AH; Stewart, D; Williams, AC, 1998) |
| "In animal models of Parkinson's disease (PD), glutamate antagonists diminish levodopa (LD)-associated motor fluctuations and dyskinesias." | 1.30 | Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. ( Blanchet, PJ; Chase, TN; Del Dotto, P; van den Munckhof, P; Verhagen Metman, L, 1998) |
| "We report a 48-year-old woman with a 17-year history of PD who developed a peripheral sensory-motor neuropathy secondary to chronic administration (8 years) of amantadine." | 1.30 | Amantadine-induced peripheral neuropathy. ( Minagar, A; Sharma, K; Shulman, LM; Weiner, WJ, 1999) |
| "Panhypopituitarism was diagnosed after measuring the basal hormone levels (ACTH, TSH, FT3, FT4, Cortisol, Prolactin, LH, FSH, ADH) and conducting the pituitary stimulation test." | 1.30 | [Virus encephalitis with symptomatic Parkinson syndrome, diabetes insipidus and panhypopituitarism]. ( Ickenstein, GW; Klotz, JM; Langohr, HD, 1999) |
| "In thirty patients with idiopathic Parkinson's disease (PD) we examined in a prospectively designed study the effect on motor performance and cognitive functions of amantadine sulphate, applied intravenously over a period of 14 days." | 1.30 | Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's disease. ( Binder, H; Birk, M; Helscher, RJ; Pinter, MM, 1999) |
| "Initiating treatment in a patient with Parkinson's disease requires consideration of age, degree of disease activity, and consequences of long-term treatment." | 1.29 | [Initiation of treatment in Parkinson disease]. ( Ghika, J, 1995) |
| "Selegiline, which was always used in combination with L-dopa, not only inhibited MAO activity, as expected, but it also appeared to induce an increase in 5HT content." | 1.29 | Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease. ( Janjua, R; Roos, RA; van Kempen, GM, 1995) |
| "Some treatments used for Parkinson's disease attenuate locomotor depression in rats treated with reserpine and alpha-methyl-p-tyrosine." | 1.29 | Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. ( Danysz, W; Quack, G; Rogoz, Z; Skuza, G, 1994) |
| "Since 1985, treatment of idiopathic Parkinson's disease (PD) by surgical transfer of adult or fetal chromaffin tissue or of fetal central neural tissue to the brains of afflicted patients has been attempted, with variable clinical results." | 1.29 | Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. ( Durso, R; Folkerth, RD, 1996) |
| "Amantadine-treated patients (n = 250) were similar to the patients not treated with amantadine (n = 586) in terms of age, gender, type of parkinsonism, Hoehn and Yahr stage and dementia status at initial neurological visit." | 1.29 | Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. ( Ahlskog, JE; Basran, P; Ho, MM; Offord, KP; Prasad, M; Rajput, A; Rajput, AH; Schroeder, DR; Uitti, RJ, 1996) |
| "Amantadine is used in the treatment of Parkinson's disease without a well established mechanism of action." | 1.28 | Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? ( Booij, J; Drukarch, B; Stoof, JC, 1992) |
| "Parkinson's disease affects thousands of Americans, men and women equally and apparently with little regard to race." | 1.28 | Treating the progressive stages of Parkinson's disease. ( Jacobs, MB; Varon, J, 1991) |
| " Memory scores were correlated with age, sex, education, marital status, length of illness, age at onset of illness, dosage and time on medication, functional status, and the major symptoms of parkinsonism." | 1.28 | Correlates of memory in Parkinson's disease. ( Reynolds, CM; Riklan, M; Stellar, S, 1989) |
| "Parkinson's disease is associated with a variety of neurotransmitter disturbances which may be further altered by its treatment with dopamine agonists." | 1.27 | Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. ( Lang, AE, 1984) |
| "The drug treatment of Parkinson's disease should be tailored to the age of the patient, coexistence of dementia or postural hypotension, duration of the disease process and the emergence of side effects." | 1.27 | The drug treatment of Parkinson's disease. ( Morris, JG, 1984) |
| "This article gives an overview of Parkinson's disease, a common neurological disorder." | 1.27 | Comprehensive care of the patient with Parkinson's disease. ( Bratton, M; Jost, MG; Lannon, MC; Lockhart-Pretti, P; Thomas, CA, 1986) |
| "Twenty patients with idiopathic Parkinson's disease (PD) and motor fluctuations received open-label amantadine (100-200 mg/d) in addition to their other antiparkinson medications." | 1.27 | Amantadine and motor fluctuations in chronic Parkinson's disease. ( Carroll, VS; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM, 1987) |
| "There were 3 miscarriages, 4 elective abortions, and 17 term pregnancies." | 1.27 | Parkinson's disease and pregnancy. ( Golbe, LI, 1987) |
| "Treatment of Parkinson's disease is not difficult in the early stages of the disease; a therapeutic regimen of carbidopa-levodopa or possibly, a combination of carbidopa-levodopa and bromocriptine, provides the best therapeutic results." | 1.27 | Pharmacotherapy: problems and practices. ( Muenter, MD, 1986) |
| "The classical clinical picture of Parkinson's disease is all too frequently encountered in the elderly patient." | 1.26 | Parkinson's disease. ( Morley, JB, 1977) |
| "It is important that Parkinson's disease be considered in the differential diagnosis of a progressively evolving hemiparesis." | 1.26 | A pseudohemipharetic form of Parkinson's disease. ( Gilbert, GJ, 1976) |
| "Amantadine has been used since 1969 in the treatment of Parkinson's disease." | 1.26 | [Circulatory disorders induced by amantidine]. ( Cloarec, M; Contamin, F; Debray, J; Graisely, B; Mignot, B; Singer, B, 1976) |
| "Five patients with Parkinson's disease, when first seen, manifested an abnormal increase in appetite." | 1.26 | Increased appetite (bulimia) in Parkinson's disease. ( Beilin, B; Herishanu, Y; Rosenberg, P, 1977) |
| "Resting tremor is present when the hands are at rest; it disappears with movement." | 1.26 | The shaking patient. Diagnosis and management of tremor. ( McKinney, AS, 1977) |
| " Side effects (hallucinations, confusion, dyskinesias) were frequent, but were usually reversible by lowering the dosage of levodopa or the accompanying anticholinergic medication." | 1.26 | Piribedil: its synergistic effect in multidrug regimens for parkinsonism. ( Feigenson, JS; McDowell, FH; Sweet, RD, 1976) |
| "Two patients with Parkinson's disease and renal insufficiency had excessively high concentrations of amantadine hydrochloride in the blood." | 1.26 | Removal of amantadine hydrochloride by dialysis in patients with renal insufficiency. ( Dunea, G; Hayashi, JA; Ing, TS; Klawans, HL; Mahurkar, SD; Markey, WS, 1976) |
| " Although directly related to daily dosage of levodopa, the myoclonus was specifically blocked by the serotonin antagonist, methysergide." | 1.25 | Levodopa-induced myoclonus. ( Bergen, D; Goetz, C; Klawans, HL, 1975) |
| "Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine." | 1.25 | Interactions of L-dopa and amantadine in patients with Parkinsonism. ( Cox, B; Danta, G; Schnieden, H; Yuill, GM, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 371 (57.97) | 18.7374 |
| 1990's | 69 (10.78) | 18.2507 |
| 2000's | 86 (13.44) | 29.6817 |
| 2010's | 79 (12.34) | 24.3611 |
| 2020's | 35 (5.47) | 2.80 |
| Authors | Studies |
|---|---|
| Duque, MD | 1 |
| Camps, P | 1 |
| Torres, E | 1 |
| Valverde, E | 1 |
| Sureda, FX | 1 |
| López-Querol, M | 1 |
| Camins, A | 1 |
| Prathalingam, SR | 1 |
| Kelly, JM | 1 |
| Vázquez, S | 1 |
| Zhang, L | 1 |
| Balan, G | 1 |
| Barreiro, G | 1 |
| Boscoe, BP | 1 |
| Chenard, LK | 1 |
| Cianfrogna, J | 1 |
| Claffey, MM | 1 |
| Chen, L | 1 |
| Coffman, KJ | 1 |
| Drozda, SE | 1 |
| Dunetz, JR | 1 |
| Fonseca, KR | 1 |
| Galatsis, P | 1 |
| Grimwood, S | 1 |
| Lazzaro, JT | 1 |
| Mancuso, JY | 1 |
| Miller, EL | 1 |
| Reese, MR | 1 |
| Rogers, BN | 1 |
| Sakurada, I | 1 |
| Skaddan, M | 1 |
| Smith, DL | 1 |
| Stepan, AF | 1 |
| Trapa, P | 1 |
| Tuttle, JB | 1 |
| Verhoest, PR | 1 |
| Walker, DP | 1 |
| Wright, AS | 1 |
| Zaleska, MM | 1 |
| Zasadny, K | 1 |
| Shaffer, CL | 1 |
| Marmol, S | 1 |
| Feldman, M | 1 |
| Singer, C | 3 |
| Margolesky, J | 1 |
| Rascol, O | 10 |
| Fabbri, M | 2 |
| Poewe, W | 7 |
| Müller, T | 8 |
| Wang, CC | 1 |
| Wu, TL | 1 |
| Lin, FJ | 1 |
| Tai, CH | 1 |
| Lin, CH | 1 |
| Wu, RM | 1 |
| Lazarova, M | 1 |
| Tancheva, L | 1 |
| Chayrov, R | 1 |
| Tzvetanova, E | 1 |
| Alexandrova, A | 1 |
| Popatanasov, A | 1 |
| Uzunova, D | 1 |
| Stefanova, M | 1 |
| Stankova, I | 1 |
| Kalfin, R | 1 |
| Tönges, L | 2 |
| deVries, T | 1 |
| Jaros, M | 1 |
| Quartel, A | 1 |
| Jacobs, D | 1 |
| Cohen, SR | 1 |
| Terry, ML | 1 |
| Coyle, M | 1 |
| Wheelis, E | 1 |
| Centner, A | 1 |
| Smith, S | 1 |
| Glinski, J | 1 |
| Lipari, N | 1 |
| Budrow, C | 1 |
| Manfredsson, FP | 1 |
| Bishop, C | 1 |
| Cennamo, M | 1 |
| Dragotto, F | 1 |
| Favuzza, E | 1 |
| Morelli, A | 1 |
| Mencucci, R | 1 |
| Takeda, A | 1 |
| Krasowska, D | 2 |
| Gerkowicz, A | 1 |
| Wróblewska-Łuczka, P | 1 |
| Grabarska, A | 1 |
| Załuska-Ogryzek, K | 1 |
| Łuszczki, JJ | 1 |
| Thomsen, M | 1 |
| Stoica, A | 1 |
| Christensen, KV | 1 |
| Fryland, T | 1 |
| Mikkelsen, JD | 1 |
| Hansen, JB | 1 |
| Przytuła, F | 2 |
| Kasprzak, J | 2 |
| Dulski, J | 2 |
| Koziorowski, D | 3 |
| Kwaśniak-Butowska, M | 2 |
| Sołtan, W | 2 |
| Roszmann, A | 2 |
| Śmiłowska, K | 2 |
| Schinwelski, M | 2 |
| Sławek, J | 3 |
| Valencia-Vásquez, A | 1 |
| Gaviria-Mendoza, A | 1 |
| Ayala-Torres, JD | 1 |
| Calvo-Torres, F | 1 |
| Machado-Alba, JE | 1 |
| Riederer, P | 7 |
| Kuhn, W | 5 |
| Kwan, C | 1 |
| Kang, W | 1 |
| Kim, E | 1 |
| Belliveau, S | 1 |
| Frouni, I | 1 |
| Huot, P | 1 |
| Murakami, Y | 1 |
| Nishijima, H | 1 |
| Nakamura, T | 1 |
| Furukawa, T | 1 |
| Kinoshita, I | 1 |
| Kon, T | 1 |
| Suzuki, C | 1 |
| Tomiyama, M | 1 |
| Pak, A | 1 |
| Chang, E | 1 |
| Pogorelov, VM | 1 |
| Martini, ML | 1 |
| Jin, J | 1 |
| Wetsel, WC | 1 |
| Caron, MG | 1 |
| Pajo, AT | 1 |
| Espiritu, AI | 1 |
| Jamora, RDG | 1 |
| Khlebtovsky, A | 1 |
| Steiner, I | 1 |
| Treves, T | 1 |
| Djaldetti, R | 1 |
| Okamoto, T | 1 |
| Vaz, RL | 1 |
| Sousa, S | 1 |
| Chapela, D | 1 |
| van der Linde, HC | 1 |
| Willemsen, R | 1 |
| Correia, AD | 1 |
| Outeiro, TF | 1 |
| Afonso, ND | 1 |
| Kestenbaum, M | 1 |
| Abu Snineh, M | 1 |
| Nussbaum, T | 1 |
| Gadoth, A | 1 |
| Rosenberg, A | 1 |
| Hindi, A | 1 |
| Zitser, J | 1 |
| Thaler, A | 1 |
| Giladi, N | 2 |
| Gurevich, T | 1 |
| Snineh, MA | 1 |
| Hajyahya, A | 1 |
| Linetsky, E | 1 |
| Eitan, R | 1 |
| Bergman, H | 1 |
| Israel, Z | 1 |
| Arkadir, D | 1 |
| Negre-Pages, L | 1 |
| Damier, P | 3 |
| Delval, A | 1 |
| Derkinderen, P | 1 |
| Destée, A | 2 |
| Meissner, WG | 1 |
| Rachdi, A | 1 |
| Tison, F | 2 |
| Perez-Lloret, S | 2 |
| Tanner, CM | 8 |
| Pahwa, R | 8 |
| Hauser, RA | 9 |
| Oertel, WH | 2 |
| Isaacson, SH | 2 |
| Jankovic, J | 2 |
| Johnson, R | 6 |
| Chernick, D | 1 |
| Hubble, J | 1 |
| Zheng, C | 1 |
| Xu, Y | 1 |
| Chen, G | 1 |
| Tan, Y | 1 |
| Zeng, W | 1 |
| Wang, J | 1 |
| Cheng, C | 1 |
| Yang, X | 1 |
| Nie, S | 1 |
| Zhang, Z | 1 |
| Cao, X | 1 |
| Moegle, C | 1 |
| Grillon, A | 1 |
| Anheim, M | 1 |
| Lipsker, D | 1 |
| Velter, C | 1 |
| Shen, W | 1 |
| Ren, W | 1 |
| Zhai, S | 1 |
| Yang, B | 1 |
| Vanoye, CG | 1 |
| Mitra, A | 1 |
| George, AL | 1 |
| Surmeier, DJ | 1 |
| AlShimemeri, S | 1 |
| Fox, SH | 2 |
| Visanji, NP | 1 |
| Rejdak, K | 2 |
| Grieb, P | 2 |
| Świątkiewicz, M | 1 |
| Prus, K | 1 |
| Poon, LH | 1 |
| Lee, AJ | 1 |
| Vuong, M | 1 |
| Zuzuarregui, JR | 1 |
| Danysz, W | 3 |
| Dekundy, A | 1 |
| Scheschonka, A | 1 |
| Islam, N | 1 |
| Rahman, S | 1 |
| Katunina, EA | 3 |
| Dos Santos, DT | 1 |
| Imthon, AK | 1 |
| Strelow, MZ | 1 |
| Pille, A | 1 |
| Schumacher-Schuh, AF | 1 |
| Vollhardt, R | 1 |
| Budowski, C | 1 |
| Manceau, P | 1 |
| Mongin, M | 1 |
| Degos, B | 1 |
| Koschel, J | 1 |
| Ray Chaudhuri, K | 1 |
| Thiel, M | 1 |
| Raeder, V | 1 |
| Jost, WH | 1 |
| Seier, M | 1 |
| Hiller, A | 1 |
| Nausieda, PA | 2 |
| Truong, DD | 2 |
| Agarwal, P | 1 |
| Hull, KL | 1 |
| Lyons, KE | 2 |
| Stempien, MJ | 3 |
| Wagle Shukla, A | 1 |
| Goetz, CG | 7 |
| Stebbins, GT | 2 |
| Chung, KA | 2 |
| Nicholas, AP | 2 |
| Merkitch, D | 1 |
| Stacy, MA | 2 |
| Oertel, W | 1 |
| Eggert, K | 1 |
| Trenkwalder, C | 3 |
| Ehret, R | 1 |
| Azulay, JP | 2 |
| Isaacson, S | 3 |
| Felt, L | 2 |
| Ryu, YK | 1 |
| Park, HY | 1 |
| Go, J | 1 |
| Choi, DH | 1 |
| Kim, YH | 1 |
| Hwang, JH | 1 |
| Noh, JR | 1 |
| Lee, TG | 1 |
| Lee, CH | 1 |
| Kim, KS | 1 |
| Loiodice, S | 1 |
| Denibaud, AS | 1 |
| Deffains, W | 1 |
| Alix, M | 1 |
| Montagne, P | 1 |
| Seffals, M | 1 |
| Drieu La Rochelle, C | 1 |
| Elmer, LW | 2 |
| Juncos, JL | 1 |
| Criswell, SR | 1 |
| Parashos, S | 1 |
| Patni, R | 4 |
| Elkurd, MT | 1 |
| Bahroo, LB | 1 |
| Wargin, WA | 1 |
| Souza-Prien, CJ | 1 |
| McClure, N | 1 |
| Nguyen, JT | 2 |
| Went, GT | 2 |
| Paik, J | 1 |
| Keam, SJ | 1 |
| Stanley, P | 1 |
| Pioli, EY | 2 |
| Kozak, R | 1 |
| Popiolek, M | 1 |
| Bezard, E | 3 |
| Jimenez-Shaheed, J | 1 |
| Malaty, IA | 1 |
| Deik, A | 1 |
| Dashtipour, K | 1 |
| Tafreshi, AR | 1 |
| Daggumilli, S | 1 |
| Vanathi, M | 1 |
| Ganger, A | 1 |
| Goyal, V | 1 |
| Tandon, R | 1 |
| Möhr, JD | 2 |
| Kremens, DE | 1 |
| Kreitzman, DL | 1 |
| Walsh, RR | 1 |
| Howard, R | 1 |
| Wilson, L | 1 |
| Sheehan, J | 1 |
| Thorpe, M | 1 |
| Salvado, M | 1 |
| Hernández-Vara, J | 1 |
| Lee, JY | 2 |
| Oh, S | 1 |
| Kim, JM | 1 |
| Kim, JS | 1 |
| Oh, E | 1 |
| Kim, HT | 1 |
| Jeon, BS | 6 |
| Cho, JW | 1 |
| Pagonabarraga, J | 1 |
| Kulisevsky, J | 2 |
| Ory-Magne, F | 2 |
| Corvol, JC | 1 |
| Bonnet, AM | 1 |
| Brefel-Courbon, C | 1 |
| Dellapina, E | 1 |
| Durif, F | 1 |
| Galitzky, M | 1 |
| Lebouvier, T | 1 |
| Meissner, W | 1 |
| Thalamas, C | 1 |
| Salis, A | 1 |
| Sommet, A | 1 |
| Viallet, F | 1 |
| Vidailhet, M | 1 |
| Rodnitzky, RL | 1 |
| Narayanan, NS | 1 |
| Sensi, M | 1 |
| Preda, F | 1 |
| Trevisani, L | 1 |
| Contini, E | 1 |
| Gragnaniello, D | 1 |
| Capone, JG | 1 |
| Sette, E | 1 |
| Golfre-Andreasi, N | 1 |
| Tugnoli, V | 1 |
| Tola, MR | 1 |
| Quatrale, R | 1 |
| Sawada, H | 2 |
| Oeda, T | 2 |
| Umemura, A | 1 |
| Tomita, S | 1 |
| Hayashi, R | 2 |
| Kohsaka, M | 1 |
| Yamamoto, K | 2 |
| Sudoh, S | 1 |
| Sugiyama, H | 1 |
| Lewitt, PA | 1 |
| Mouradian, MM | 2 |
| Ahlskog, JE | 2 |
| Friedman, JH | 1 |
| Sethi, K | 1 |
| Truong, D | 1 |
| Struck, L | 1 |
| Ruby, AE | 1 |
| McClure, NL | 1 |
| Mazzucchi, S | 1 |
| Frosini, D | 1 |
| Bonuccelli, U | 3 |
| Ceravolo, R | 2 |
| Bortolanza, M | 1 |
| Bariotto-Dos-Santos, KD | 1 |
| Dos-Santos-Pereira, M | 1 |
| da-Silva, CA | 1 |
| Del-Bel, E | 1 |
| Vijayakumar, D | 1 |
| Lee, PY | 1 |
| Tu, HP | 1 |
| Lin, CP | 1 |
| Chang, CH | 1 |
| Cheng, KC | 1 |
| Lin, CC | 1 |
| Hsu, SL | 1 |
| Thomsen, BL | 1 |
| Herz, DM | 1 |
| Siebner, HR | 1 |
| Løkkegaard, A | 1 |
| Hong, CT | 1 |
| Sun, Y | 1 |
| Lu, CJ | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Moritoyo, T | 1 |
| Yabe, H | 1 |
| Nomoto, M | 3 |
| Stegmeier-Petroianu, A | 1 |
| Petroianu, GA | 1 |
| Letvinenko, IV | 1 |
| Odinak, MM | 1 |
| Mogil'naia, VI | 1 |
| Chang, KC | 2 |
| Kim, MK | 2 |
| Wee, WR | 2 |
| Lee, JH | 2 |
| Pond, A | 1 |
| Lee, MS | 1 |
| Hardten, DR | 1 |
| Harrison, AR | 1 |
| Krachmer, JH | 1 |
| Husain, M | 1 |
| Shukla, R | 1 |
| Dikshit, M | 1 |
| Maheshwari, PK | 1 |
| Nag, D | 1 |
| Srimal, RC | 1 |
| Seth, PK | 1 |
| Khanna, VK | 1 |
| Stacy, M | 3 |
| Park, CY | 1 |
| Chuck, RS | 1 |
| Ikeda, K | 1 |
| Yoshikawa, S | 1 |
| Kurokawa, T | 1 |
| Yuzawa, N | 1 |
| Nakao, K | 1 |
| Mochizuki, H | 1 |
| Yamaguchi, S | 1 |
| Katsumata, Y | 1 |
| Mimura, M | 1 |
| Jeong, JH | 1 |
| Zhe, X | 1 |
| Qu, QM | 1 |
| Wang, RL | 1 |
| Cao, HM | 1 |
| Qiao, J | 1 |
| Guo, F | 1 |
| Kassubek, J | 1 |
| Büttner, T | 2 |
| Reichmann, H | 2 |
| Schulz, JB | 1 |
| Wüllner, U | 1 |
| Csoti, I | 1 |
| Wolf, E | 1 |
| Seppi, K | 2 |
| Katzenschlager, R | 1 |
| Hochschorner, G | 1 |
| Ransmayr, G | 1 |
| Schwingenschuh, P | 1 |
| Ott, E | 1 |
| Kloiber, I | 1 |
| Haubenberger, D | 1 |
| Auff, E | 1 |
| Yeh, HH | 1 |
| Yang, YH | 1 |
| Chen, SH | 1 |
| Stefanis, N | 1 |
| Bozi, M | 1 |
| Christodoulou, C | 1 |
| Douzenis, A | 1 |
| Gasparinatos, G | 1 |
| Stamboulis, E | 1 |
| Stefanis, C | 1 |
| Stefanis, L | 1 |
| Gondim, Fde A | 1 |
| Costa, HA | 1 |
| Taunay, TC | 1 |
| de Oliveira, GR | 1 |
| Ferreira, JM | 1 |
| Rola, FH | 1 |
| Iablonskaia, AIu | 1 |
| Fedorova, NV | 1 |
| Bel'gusheva, ME | 1 |
| Thomas, A | 3 |
| Bonanni, L | 1 |
| Gambi, F | 1 |
| Di Iorio, A | 2 |
| Onofrj, M | 3 |
| Fasano, A | 1 |
| Ricciardi, L | 1 |
| Pettorruso, M | 1 |
| Bentivoglio, AR | 1 |
| Weintraub, D | 1 |
| Sohr, M | 1 |
| Potenza, MN | 1 |
| Siderowf, AD | 1 |
| Voon, V | 1 |
| Whetteckey, J | 1 |
| Wunderlich, GR | 1 |
| Lang, AE | 5 |
| Deogaonkar, M | 1 |
| Wilson, K | 1 |
| Vitek, J | 1 |
| Kuno, S | 3 |
| Yamamoto, M | 1 |
| Hisanaga, K | 1 |
| Kawamura, T | 1 |
| Kim, HJ | 3 |
| Kim, YE | 3 |
| Yun, JY | 3 |
| Lee, MJ | 1 |
| Wang, K | 1 |
| Kim, IS | 1 |
| Lee, BH | 1 |
| Han, HS | 1 |
| Lozano, A | 1 |
| Stern, M | 1 |
| Fisone, G | 1 |
| Kobylecki, C | 1 |
| Hill, MP | 1 |
| Crossman, AR | 1 |
| Ravenscroft, P | 1 |
| Walsh, RA | 1 |
| Stagg, P | 1 |
| Grice, T | 1 |
| Fernandez, HH | 2 |
| Rana, AQ | 1 |
| Masroor, MS | 1 |
| Hubsher, G | 1 |
| Haider, M | 1 |
| Okun, MS | 2 |
| Tarsy, D | 2 |
| Elahi, B | 1 |
| Phielipp, N | 1 |
| Chen, R | 1 |
| Joutsa, J | 1 |
| Martikainen, K | 1 |
| Vahlberg, T | 1 |
| Kaasinen, V | 1 |
| Avendaño-Cantos, EM | 1 |
| Celis-Sánchez, J | 1 |
| Mesa-Varona, D | 1 |
| Gálvez-Martínez, J | 1 |
| López-Arroquia, E | 1 |
| González Del Valle, F | 1 |
| Fedorova, TN | 1 |
| Bagyeva, GKh | 1 |
| Dobrotvorskaia, IS | 1 |
| Stepanova, MS | 1 |
| Polevaia, EV | 1 |
| Ivanova-Smolenskaia, IA | 1 |
| Illarioshkin, SN | 1 |
| Yang, HJ | 1 |
| Gu, N | 1 |
| Yoon, SH | 1 |
| Cho, JY | 1 |
| Chan, HF | 1 |
| Kukkle, PL | 1 |
| Merello, M | 3 |
| Lim, SY | 1 |
| Poon, YY | 1 |
| Moro, E | 1 |
| Aron Badin, R | 1 |
| Spinnewyn, B | 1 |
| Gaillard, MC | 1 |
| Jan, C | 1 |
| Malgorn, C | 1 |
| Van Camp, N | 1 |
| Dollé, F | 1 |
| Guillermier, M | 1 |
| Boulet, S | 1 |
| Bertrand, A | 1 |
| Savasta, M | 1 |
| Auguet, M | 1 |
| Brouillet, E | 1 |
| Chabrier, PE | 1 |
| Hantraye, P | 1 |
| Tronci, E | 1 |
| Li, Q | 1 |
| Porras, G | 1 |
| Björklund, A | 1 |
| Carta, M | 1 |
| Miyasaki, JM | 2 |
| Nutt, JG | 1 |
| Urkowitz, A | 1 |
| Jaglin, JA | 1 |
| Ge, S | 1 |
| Karaban', IN | 1 |
| Lukhanina, EP | 1 |
| Kapustina, MT | 1 |
| Karasevich, NV | 1 |
| Moresco, RM | 2 |
| Volonte, MA | 2 |
| Messa, C | 2 |
| Gobbo, C | 2 |
| Galli, L | 1 |
| Carpinelli, A | 2 |
| Rizzo, G | 2 |
| Panzacchi, A | 1 |
| Franceschi, M | 1 |
| Fazio, F | 2 |
| Blanchet, PJ | 2 |
| Metman, LV | 2 |
| Chase, TN | 5 |
| Gille, G | 1 |
| Przuntek, H | 5 |
| Riess, O | 1 |
| Schwartz, A | 1 |
| Schwarz, J | 3 |
| Vogt, T | 1 |
| Crosby, N | 1 |
| Deane, KH | 2 |
| Clarke, CE | 4 |
| Schulte, T | 1 |
| Crosby, NJ | 1 |
| Ebersbach, G | 1 |
| Tanaka, M | 1 |
| Okamoto, K | 1 |
| Romrell, J | 1 |
| Ceballos-Baumann, A | 1 |
| Iacono, D | 1 |
| Luciano, AL | 1 |
| Armellino, K | 1 |
| Sobolewski, P | 1 |
| Takáts, A | 1 |
| Zach, M | 1 |
| Friedman, A | 2 |
| Derejko, M | 1 |
| Furukawa, Y | 1 |
| Filiano, JJ | 1 |
| Kish, SJ | 1 |
| Avakian, GN | 2 |
| Voronina, TA | 2 |
| Val'dman, EA | 2 |
| Nerobkova, LN | 2 |
| Samoĭlova, EV | 1 |
| Jung, SK | 1 |
| Charles, PD | 1 |
| Padaliya, BB | 1 |
| Newman, WJ | 1 |
| Gill, CE | 1 |
| Covington, CD | 1 |
| Fang, JY | 1 |
| So, SA | 1 |
| Tramontana, MG | 1 |
| Konrad, PE | 1 |
| Davis, TL | 1 |
| Allers, KA | 1 |
| Bergstrom, DA | 1 |
| Ghazi, LJ | 1 |
| Kreiss, DS | 1 |
| Walters, JR | 1 |
| Johnston, TH | 1 |
| Lee, J | 1 |
| Gomez-Ramirez, J | 1 |
| Brotchie, JM | 1 |
| Kurlan, R | 1 |
| Papapetropoulos, S | 1 |
| Gonzalez, MA | 1 |
| Roberts, EL | 1 |
| Lieberman, A | 1 |
| Sampaio, C | 1 |
| Waters, C | 1 |
| Arakelian, RK | 1 |
| Kapitsa, IG | 1 |
| Gusev, EI | 1 |
| Storch, A | 2 |
| Oehlwein, C | 2 |
| Winkelmann, J | 1 |
| Polzer, U | 2 |
| Hundemer, HP | 1 |
| da Silva-Júnior, FP | 1 |
| Braga-Neto, P | 1 |
| Sueli Monte, F | 1 |
| de Bruin, VM | 1 |
| Lees, A | 1 |
| Kitagawa, M | 1 |
| Tashiro, K | 1 |
| Swick, BL | 1 |
| Walling, HW | 1 |
| Artem'ev, DV | 1 |
| Odin, P | 2 |
| Werner, G | 1 |
| Renner, R | 1 |
| Shing, M | 1 |
| Ludolph, A | 1 |
| Schüler, P | 1 |
| Antico, J | 1 |
| Obeso, JA | 1 |
| Doan, J | 1 |
| Whishaw, IQ | 1 |
| Pellis, SM | 1 |
| Suchowersky, O | 2 |
| Brown, LA | 1 |
| Hayes, BB | 1 |
| Cook-Norris, RH | 1 |
| Miller, JL | 1 |
| Rodriguez, A | 1 |
| Zic, JA | 1 |
| Swarztrauber, K | 1 |
| Koudelka, C | 1 |
| Brodsky, MA | 1 |
| Inzelberg, R | 1 |
| Schechtman, E | 1 |
| Miniowich, A | 1 |
| Strugatsky, R | 1 |
| Logi, C | 1 |
| Rossi, C | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| Deutschländer, A | 1 |
| Asmus, F | 1 |
| Marelli, E | 1 |
| Klopstock, T | 1 |
| Gasser, T | 1 |
| Bötzel, K | 1 |
| Salgado, JC | 1 |
| Gutknecht, DR | 1 |
| Benbir, G | 1 |
| Ozekmekçi, S | 1 |
| Cinar, M | 1 |
| Beskardes, F | 1 |
| Apaydin, H | 1 |
| Erginöz, E | 1 |
| Giroux, ML | 1 |
| Kubo, S | 1 |
| Iwatake, A | 1 |
| Ebihara, N | 1 |
| Murakami, A | 1 |
| Hattori, N | 1 |
| Dell'Antone, P | 1 |
| IbnLkayat, M | 1 |
| Drago, D | 1 |
| Zatta, P | 1 |
| Wolters, A | 1 |
| Benecke, R | 1 |
| Korczyn, AD | 2 |
| Jon Stoessl, A | 1 |
| Watts, RL | 1 |
| De Deyn, PP | 1 |
| Kashihara, K | 1 |
| Imamura, T | 1 |
| Chen, JJ | 1 |
| Swope, DM | 1 |
| Cheng, PL | 1 |
| Hung, SW | 1 |
| Lin, LW | 1 |
| Chong, CF | 1 |
| Lau, CI | 1 |
| Whitney, CM | 1 |
| Klivényi, P | 1 |
| Vécsei, L | 1 |
| Teräväinen, H | 1 |
| Larsen, TA | 1 |
| Weiner, M | 1 |
| Colucci d'Amato, C | 2 |
| Puccini, A | 1 |
| Cristillo, A | 1 |
| Vizioli, R | 1 |
| Burton, K | 1 |
| Calne, DB | 5 |
| Jörg, J | 1 |
| Biesemeyer, H | 1 |
| Ludin, HP | 2 |
| Ringwald, E | 2 |
| Mancall, EL | 1 |
| Covington, TR | 1 |
| Alonso, RJ | 1 |
| Quinn, NP | 2 |
| Morris, JG | 2 |
| Daugirdas, JT | 2 |
| Ing, IL | 1 |
| Cheng, PJ | 1 |
| Wu, MJ | 1 |
| Klawans, HL | 6 |
| Soung, LS | 2 |
| Wilson, TW | 1 |
| Rajput, AH | 3 |
| Schneider, E | 4 |
| Fischer, PA | 3 |
| Clemens, R | 3 |
| Balzereit, F | 1 |
| Fünfgeld, EW | 5 |
| Haase, HJ | 1 |
| Uono, M | 1 |
| Wheatley, D | 1 |
| Kadykov, AS | 4 |
| Wesemann, W | 2 |
| Sturm, G | 1 |
| Mastrosimone, F | 1 |
| De Angelis, G | 1 |
| Iaccarino, C | 1 |
| Giordano, L | 1 |
| Marmo, E | 1 |
| Ando, K | 1 |
| Shiozawa, R | 1 |
| Kase, M | 1 |
| Kuroiwa, Y | 1 |
| Narabayashi, H | 1 |
| Nishitani, Y | 1 |
| Ohmoto, T | 1 |
| Toyokura, Y | 1 |
| Uono, K | 1 |
| Muenter, MD | 2 |
| Sandyk, R | 2 |
| Gründig, E | 2 |
| Gerstenbrand, F | 4 |
| Stewart, RM | 1 |
| Hausner, RS | 1 |
| Ing, TS | 2 |
| Ideshita, H | 1 |
| Morita, H | 1 |
| Yoshinaga, J | 2 |
| Sasaki, T | 1 |
| Hikiji, A | 2 |
| Pfaff, G | 1 |
| Ghika, J | 1 |
| Couban, S | 1 |
| van Kempen, GM | 1 |
| Janjua, R | 1 |
| Roos, RA | 3 |
| Sweeney, PJ | 1 |
| Skuza, G | 1 |
| Rogoz, Z | 1 |
| Quack, G | 3 |
| Zhang, WC | 1 |
| Ding, YJ | 1 |
| Cao, JK | 1 |
| Du, JX | 1 |
| Zhang, GF | 1 |
| Liu, YJ | 1 |
| Mitsui, T | 1 |
| Kawai, H | 1 |
| Sakoda, S | 1 |
| Miyata, M | 1 |
| Saito, S | 1 |
| Quinn, N | 1 |
| Hineno, T | 1 |
| Mizobuchi, M | 1 |
| Nishimatsu, O | 1 |
| Horiguchi, J | 2 |
| Kakimoto, Y | 2 |
| Chi, EM | 2 |
| Bower, DJ | 1 |
| Chalasani, P | 1 |
| Ammons, JC | 1 |
| Nogaki, H | 1 |
| Morimatsu, M | 1 |
| Weller, M | 1 |
| Kornhuber, J | 2 |
| Jellinger, K | 1 |
| Danielczyk, W | 5 |
| Gsell, W | 1 |
| Folkerth, RD | 1 |
| Durso, R | 1 |
| Brownlee, HJ | 1 |
| Uitti, RJ | 3 |
| Offord, KP | 1 |
| Schroeder, DR | 1 |
| Ho, MM | 1 |
| Prasad, M | 1 |
| Rajput, A | 1 |
| Basran, P | 1 |
| Patzold, T | 1 |
| Kishore, A | 1 |
| Snow, BJ | 1 |
| Colosimo, C | 1 |
| Pontieri, FE | 1 |
| Noveske, FG | 1 |
| Pfeiffer, RF | 1 |
| Greulich, W | 1 |
| Fenger, E | 1 |
| Rundshagen, I | 1 |
| Menzaghi, F | 1 |
| Whelan, KT | 1 |
| Risbrough, VB | 1 |
| Rao, TS | 1 |
| Lloyd, GK | 1 |
| Ogawa, N | 1 |
| Ajax, T | 1 |
| Rodnitzky, R | 1 |
| Dobson, J | 1 |
| Dike, GL | 1 |
| Adler, CH | 1 |
| Stern, MB | 1 |
| Vernon, G | 1 |
| Hurtig, HI | 1 |
| Scheidtmann, K | 1 |
| López-Villegas, D | 1 |
| Nakamura, Y | 1 |
| Endo, S | 1 |
| Hagell, P | 1 |
| Vinge, E | 1 |
| van Laar, T | 1 |
| Lammers, GJ | 1 |
| Gerritsen, JJ | 1 |
| Meinders, AE | 1 |
| Löffler, H | 1 |
| Habermann, B | 1 |
| Effendy, I | 1 |
| Nieuwboer, A | 1 |
| De Weerdt, W | 1 |
| Dom, R | 1 |
| Lesaffre, E | 1 |
| Verhagen Metman, L | 2 |
| Del Dotto, P | 3 |
| van den Munckhof, P | 2 |
| Fang, J | 1 |
| Factor, SA | 2 |
| Molho, ES | 2 |
| Brown, DL | 1 |
| Silver, DE | 4 |
| Ruggieri, S | 3 |
| Bhatia, K | 1 |
| Brooks, DJ | 1 |
| Burn, DJ | 1 |
| Playfer, J | 1 |
| Sawle, GV | 1 |
| Schapira, AH | 1 |
| Stewart, D | 1 |
| Williams, AC | 1 |
| Bennett, VL | 1 |
| Juorio, AV | 1 |
| Li, XM | 1 |
| van Hilten, JJ | 1 |
| Grimes, D | 1 |
| Huber, TJ | 1 |
| Dietrich, DE | 1 |
| Emrich, HM | 1 |
| Wandinger, KP | 1 |
| Hagenah, JM | 1 |
| Klüter, H | 1 |
| Rothermundt, M | 1 |
| Peters, M | 1 |
| Vieregge, P | 1 |
| Shulman, LM | 1 |
| Minagar, A | 1 |
| Sharma, K | 1 |
| Weiner, WJ | 1 |
| Ickenstein, GW | 1 |
| Klotz, JM | 1 |
| Langohr, HD | 1 |
| Marjama-Lyons, J | 1 |
| Koller, W | 1 |
| Pinter, MM | 1 |
| Birk, M | 1 |
| Helscher, RJ | 1 |
| Binder, H | 1 |
| Luginger, E | 1 |
| Wenning, GK | 1 |
| Bösch, S | 1 |
| Münchau, A | 1 |
| Bhatia, KP | 1 |
| Saito, R | 1 |
| Masuda, H | 1 |
| Oshitani, H | 1 |
| Suzuki, H | 1 |
| Kawasaki, S | 1 |
| Sato, H | 1 |
| Cersósimo, MG | 1 |
| Scorticati, MC | 1 |
| Micheli, FE | 1 |
| Růzicka, E | 1 |
| Streitová, H | 1 |
| Jech, R | 1 |
| Kanovský, P | 1 |
| Roth, J | 1 |
| Rektorová, I | 1 |
| Mecír, P | 1 |
| Hortová, H | 1 |
| Bares, M | 1 |
| Hejduková, B | 1 |
| Rektor, I | 1 |
| Iwata, S | 1 |
| Kaseda, S | 1 |
| Malsch, U | 1 |
| Bliesath, H | 1 |
| Böther, K | 1 |
| Ramm, H | 1 |
| Lühmann, R | 1 |
| Treves, TA | 1 |
| Simon, ES | 1 |
| Shabtai, H | 1 |
| Orlov, Y | 1 |
| Kandinov, B | 1 |
| Paleacu, D | 1 |
| Iwahashi, J | 1 |
| Tsuji, K | 1 |
| Ishibashi, T | 1 |
| Kajiwara, J | 1 |
| Imamura, Y | 1 |
| Mori, R | 1 |
| Hara, K | 1 |
| Kashiwagi, T | 1 |
| Ohtsu, Y | 1 |
| Hamada, N | 1 |
| Maeda, H | 1 |
| Toyoda, M | 1 |
| Toyoda, T | 1 |
| Pavese, N | 1 |
| Gambaccini, G | 1 |
| Bernardini, S | 1 |
| Comi, G | 1 |
| Paci, C | 1 |
| Tribl, GG | 1 |
| Wöber, C | 1 |
| Schönborn, V | 1 |
| Brücke, T | 1 |
| Deecke, L | 1 |
| Panzer, S | 1 |
| Bandini, F | 1 |
| Pierantozzi, M | 1 |
| Bodis-Wollner, I | 1 |
| Ceballos-Baumann, AO | 1 |
| Greer, M | 3 |
| Casacchia, M | 6 |
| Carolei, A | 1 |
| Zamponi, A | 1 |
| Agnoli, A | 3 |
| Fazio, C | 1 |
| Morley, JB | 1 |
| Winkelman, AC | 1 |
| Wieck, HH | 1 |
| Kaumeier, S | 1 |
| Hungerbühler, JP | 1 |
| Regli, F | 1 |
| Vale, JA | 1 |
| Maclean, KS | 1 |
| Parkers, JD | 1 |
| Marsden, CD | 7 |
| Price, P | 1 |
| Gilbert, GJ | 1 |
| Postma, JU | 1 |
| Van Tilburg, W | 1 |
| Cloarec, M | 1 |
| Singer, B | 1 |
| Mignot, B | 1 |
| Contamin, F | 1 |
| Graisely, B | 1 |
| Debray, J | 1 |
| Hill, JW | 1 |
| Barbeau, A | 3 |
| Campanella, G | 2 |
| Butterworth, RF | 1 |
| Yamada, K | 1 |
| McFarland, HR | 1 |
| Gilbert, JC | 1 |
| Taylor, J | 1 |
| Rosenberg, P | 1 |
| Herishanu, Y | 1 |
| Beilin, B | 1 |
| Savery, F | 2 |
| Gehlen, W | 2 |
| Jacobi, P | 4 |
| Schönberger, B | 1 |
| Fahn, S | 4 |
| Timberlake, WH | 1 |
| Vance, MA | 1 |
| Parkes, D | 2 |
| Dette-Wildenhahn, G | 1 |
| Fellehner, H | 1 |
| Kamenetskiĭ, VK | 1 |
| Filipová, M | 1 |
| Balík, J | 1 |
| Filip, V | 1 |
| Rodný, J | 1 |
| Krejcová, H | 1 |
| Kundu, BC | 1 |
| Borison, RL | 1 |
| Selby, G | 1 |
| Mindham, RH | 2 |
| Parkes, JD | 10 |
| Gonce, M | 1 |
| Kunz, F | 1 |
| Lörincz, P | 1 |
| Couto, B | 1 |
| Oliveira, C | 1 |
| Mattos, JP | 1 |
| Freitas, MR | 1 |
| Butzer, JF | 1 |
| Sahs, AL | 3 |
| Isgreen, WP | 1 |
| Diehl, LW | 4 |
| McKinney, AS | 1 |
| Houeland, T | 1 |
| Slettnes, O | 1 |
| Sjaastad, O | 1 |
| Lenman, JA | 3 |
| Turnbull, MJ | 3 |
| Reid, A | 1 |
| Fleming, AM | 1 |
| Schubert, U | 1 |
| Fischer, GJ | 1 |
| Glass, J | 2 |
| Webster, DD | 1 |
| Mortimer, JA | 1 |
| Feigenson, JS | 1 |
| Sweet, RD | 1 |
| McDowell, FH | 1 |
| Kaste, M | 1 |
| Iivanainen, M | 3 |
| Mahurkar, SD | 1 |
| Dunea, G | 1 |
| Hayashi, JA | 1 |
| Markey, WS | 1 |
| Bianchine, JR | 3 |
| Pakszys, W | 1 |
| Cotzias, GC | 1 |
| Papavasiliou, PS | 1 |
| Ginos, JZ | 1 |
| Kistenev, BA | 1 |
| Pivovarova, VM | 1 |
| Nikolić, M | 1 |
| Lević, Z | 1 |
| Evtushenko, SK | 1 |
| Kandel', EI | 1 |
| Iadgarov, IS | 1 |
| Murayama, S | 1 |
| Goetz, C | 1 |
| Bergen, D | 1 |
| Pilling, JB | 1 |
| Baker, J | 1 |
| Iversen, LL | 1 |
| Iversen, SD | 1 |
| Robbins, T | 1 |
| Bovill, KT | 1 |
| Phipps, JA | 1 |
| Rose, P | 1 |
| Asselman, P | 1 |
| Callaghan, N | 1 |
| Fitzpatrick, E | 1 |
| O'Mahony, JB | 1 |
| Costall, B | 2 |
| Naylor, RJ | 2 |
| Pendefunda, G | 1 |
| Pollingher, B | 1 |
| Stefanache, F | 1 |
| Gavril, A | 1 |
| Oprisan, C | 1 |
| Merling, M | 1 |
| Nemteanu, E | 1 |
| Ciunru, M | 1 |
| Koropitzer, I | 1 |
| Boczán, G | 1 |
| Borus, F | 1 |
| Rózsa, L | 1 |
| Lipper, S | 1 |
| Bermanzohn, PC | 1 |
| Bailey, EV | 1 |
| Stone, TW | 1 |
| Godwin-Austen, R | 1 |
| Kamianov, IM | 1 |
| Andrezinia, RA | 1 |
| Damielczyk, W | 1 |
| Struppler, A | 1 |
| Velho-Groneberg, P | 1 |
| Parkenberg, H | 1 |
| Stoof, JC | 1 |
| Booij, J | 1 |
| Drukarch, B | 1 |
| Koller, WC | 2 |
| Siemers, E | 1 |
| Nakashima, K | 1 |
| Takahashi, K | 1 |
| Varon, J | 1 |
| Jacobs, MB | 1 |
| Wiggs, JW | 1 |
| Robertson, DR | 1 |
| George, CF | 1 |
| Liberzon, I | 1 |
| Dequardo, JR | 1 |
| Silk, KR | 1 |
| de Roin, S | 1 |
| Winters, S | 1 |
| Thiessen, B | 1 |
| Riklan, M | 1 |
| Reynolds, CM | 1 |
| Stellar, S | 1 |
| Brenner, M | 2 |
| Haass, A | 2 |
| Schimrigk, K | 2 |
| Harvey, NS | 1 |
| Huber, M | 1 |
| Lannon, MC | 1 |
| Thomas, CA | 1 |
| Bratton, M | 1 |
| Jost, MG | 1 |
| Lockhart-Pretti, P | 1 |
| Birkmayer, W | 4 |
| Aminoff, MJ | 1 |
| Aoki, FY | 1 |
| Sitar, DS | 1 |
| Shannon, KM | 1 |
| Carroll, VS | 1 |
| Wilson, JA | 1 |
| Farquhar, DL | 1 |
| Primrose, WR | 1 |
| Smith, RG | 1 |
| Lieberman, AN | 1 |
| Iizuka, J | 1 |
| Fischer, R | 1 |
| Iacono, RP | 1 |
| Snider, SR | 1 |
| Golbe, LI | 1 |
| Staal-Schreinemachers, AL | 1 |
| Wesseling, H | 1 |
| Lakke, JP | 1 |
| Fonda, D | 1 |
| Wirz, D | 1 |
| Greenberg, R | 1 |
| Meyers, BS | 1 |
| Inami, Y | 1 |
| Miyoshi, N | 1 |
| Peiró Grasa, A | 1 |
| Grau-Veciana, JM | 1 |
| Sandrini, G | 1 |
| Alfonsi, E | 1 |
| Martignoni, E | 1 |
| Horowski, R | 1 |
| Nappi, G | 1 |
| Pearce, J | 4 |
| Rao, NS | 2 |
| Baxter, RC | 4 |
| Curzon, G | 1 |
| Knill-Jones, RP | 5 |
| Knott, PJ | 1 |
| Tattersall, R | 1 |
| Vollum, D | 1 |
| Zilkha, KJ | 4 |
| Puca, FM | 6 |
| Bricolo, A | 3 |
| Turella, G | 2 |
| Soyka, D | 1 |
| Calver, DM | 1 |
| Millac, P | 2 |
| Hasan, I | 2 |
| Espir, ML | 2 |
| Slyfield, DG | 2 |
| Fieschi, C | 3 |
| Nardini, M | 3 |
| Tedone, ME | 2 |
| Hunter, KR | 2 |
| Stern, GM | 2 |
| Laurence, DR | 2 |
| Armitage, P | 2 |
| Marsden, P | 1 |
| Scotti, G | 1 |
| Reitano, M | 1 |
| Robotti, E | 2 |
| Godwin-Austen, RB | 1 |
| Frears, CC | 1 |
| Bergmann, S | 1 |
| Herson, RN | 1 |
| Merrick, EM | 1 |
| Schmitt, PP | 1 |
| Penders, C | 2 |
| Klawans, H | 1 |
| Ilahi, MM | 1 |
| Shenker, D | 1 |
| Di Perri, R | 1 |
| Livrea, P | 1 |
| Messina, C | 2 |
| Tomasello, F | 2 |
| Maxion, H | 1 |
| Ziegler, B | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Di Rosa, AE | 2 |
| Ambrozi, L | 1 |
| Neumayer, E | 2 |
| Simon, P | 1 |
| Malatray, J | 1 |
| Boissier, JR | 1 |
| Shibasaki, H | 1 |
| Shimomura, SK | 1 |
| Shibazaki, H | 1 |
| Young, RR | 5 |
| Matsumoto, K | 1 |
| Omoto, T | 1 |
| Beck, H | 1 |
| Balunov, OA | 1 |
| Bazhin, EF | 1 |
| Morozova, ES | 1 |
| Fedotenkova, TN | 1 |
| Pryszmont, M | 1 |
| Jankowicz, E | 1 |
| Eljasz, L | 1 |
| Slizewski, M | 1 |
| Wiśniewska, Z | 1 |
| Gospavić, J | 1 |
| Vidaković, Z | 1 |
| Megna, GF | 2 |
| Masi, G | 1 |
| Specchio, LM | 1 |
| Topel, JL | 1 |
| MacFadyen, DJ | 1 |
| Picton, TW | 1 |
| Zeldowicz, L | 1 |
| McGeer, PL | 1 |
| Cooper, P | 1 |
| Andrews, CJ | 1 |
| Fehling, C | 2 |
| Kytomaki, O | 2 |
| Nousiainen, R | 2 |
| Pekkarinen, A | 2 |
| Rinne, U | 1 |
| Siirtola, T | 2 |
| Sonninen, V | 3 |
| Viljanen, M | 2 |
| Forssman, B | 2 |
| Kihlstrand, S | 2 |
| Larsson, LE | 2 |
| Janowsky, DS | 1 |
| el-Yousef, MK | 1 |
| Davis, JM | 1 |
| Sekerke, HJ | 1 |
| Morris, DR | 1 |
| Decker, B | 1 |
| Campbell, AM | 1 |
| Williams, MJ | 1 |
| Yahr, MD | 1 |
| Duvoisin, RC | 1 |
| Walker, JE | 2 |
| Albers, JW | 2 |
| Tourtellotte, WW | 2 |
| Henderson, WG | 2 |
| Potvin, AR | 2 |
| Smith, A | 1 |
| Wanger, SL | 1 |
| Rinne, UK | 4 |
| Dallos, V | 2 |
| Heathfield, K | 2 |
| Stone, P | 2 |
| Allen, F | 1 |
| Ngai, SH | 1 |
| Hodkinson, HM | 1 |
| Pollock, M | 2 |
| Jorgensen, PB | 2 |
| Ferrari, P | 1 |
| Dupont, E | 1 |
| Sigwald, J | 4 |
| Raymondeaud, C | 3 |
| Grégoire, J | 1 |
| Rao, SK | 1 |
| Vakil, SD | 1 |
| Hilson, A | 1 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Benesová, O | 1 |
| Tolosa, E | 1 |
| Zeldowicz, LR | 1 |
| Hubermann, J | 1 |
| Völler, GW | 4 |
| Deze, J | 1 |
| Hakkarainen, H | 1 |
| Viukari, M | 1 |
| Repa, BS | 1 |
| Stribley, RF | 1 |
| Sunyapridakul, L | 1 |
| Kelly, JT | 1 |
| Zimmermann, RL | 1 |
| Abuzzahab, FS | 1 |
| Schiele, BC | 1 |
| Kravitz, EA | 1 |
| Hollmann, TD | 1 |
| Muschard, F | 1 |
| Callagham, N | 1 |
| Mcllroy, M | 1 |
| O'Connor, M | 2 |
| Calaghan, N | 1 |
| McIlroy, M | 1 |
| Blomberg, LH | 1 |
| Strömberg, U | 1 |
| Svensson, T | 1 |
| Gilland, O | 1 |
| Meyerson, B | 1 |
| Jones, DG | 2 |
| Robertson, MA | 2 |
| Lhermitte, F | 1 |
| Degos, CF | 1 |
| Ciuca, I | 1 |
| Bulandra, R | 2 |
| Serbanesco, A | 2 |
| Ninosu, N | 2 |
| Schwab, RS | 5 |
| Poskanzer, DC | 2 |
| England, AC | 3 |
| Reveno, WS | 2 |
| Bauer, RB | 3 |
| Rosenbaum, H | 2 |
| Pakkenberg, H | 1 |
| Man'kovskii, NB | 1 |
| Vainshtok, AB | 1 |
| Oleinik, LI | 1 |
| Kiseleva, AM | 1 |
| Zlydnikov, DM | 1 |
| Mazhinskaia, VP | 1 |
| Lebedeva, VK | 1 |
| Zakharova, NG | 1 |
| Harper, RW | 1 |
| Knothe, BU | 1 |
| Cox, B | 1 |
| Danta, G | 1 |
| Schnieden, H | 1 |
| Yuill, GM | 1 |
| Danielcyk, W | 1 |
| Wolf, SM | 1 |
| Davis, RL | 1 |
| Brait, K | 1 |
| Schwarz, GA | 2 |
| Weinmann, RL | 1 |
| Umbach, W | 1 |
| Oppel, F | 1 |
| Hirschmann, J | 1 |
| Peaston, MJ | 1 |
| Messiha, FS | 1 |
| Siegfried, J | 1 |
| Massara, F | 1 |
| Camanni, F | 1 |
| Molinatti, GM | 1 |
| Cincă, I | 1 |
| Holmsen, R | 1 |
| Presthus, J | 1 |
| Molnár, G | 1 |
| Fodor, A | 1 |
| Woods, AC | 1 |
| Glaubiger, GA | 1 |
| Kalsbeek, GL | 1 |
| Koopmans-van Dorp, B | 1 |
| van Ketel, WG | 1 |
| Goedhart-van Dijk, B | 1 |
| Rees, JE | 1 |
| Pearce, LA | 2 |
| Waterbury, LD | 2 |
| Green, HD | 1 |
| McHenry, JT | 1 |
| Delwaide, PJ | 4 |
| Weeth, JB | 2 |
| Shealy, CN | 2 |
| Mercier, DA | 1 |
| Boman, K | 2 |
| Porras, J | 2 |
| Allen, FA | 1 |
| Appleton, DB | 2 |
| Eadie, MJ | 2 |
| Sutherland, JM | 2 |
| Gilligan, BS | 1 |
| Veale, J | 1 |
| Wodak, J | 1 |
| Kivalo, E | 1 |
| Clements, PJ | 1 |
| Baxter, R | 1 |
| Piot, C | 1 |
| Bergin, JD | 1 |
| Haas, L | 1 |
| Cuningham, JA | 1 |
| Morah, DD | 1 |
| Robinson, RG | 1 |
| Spears, GF | 1 |
| Freedman, BE | 1 |
| Getz, E | 1 |
| MacGregor, JM | 1 |
| Ames, FR | 1 |
| Mars, H | 1 |
| Botez, MI | 1 |
| Joubert, M | 1 |
| Mann, DC | 1 |
| Laitinen, LV | 1 |
| Vilkki, J | 1 |
| Albert, E | 1 |
| Giuffrè, R | 2 |
| Gambacorta, D | 2 |
| Pearce, I | 1 |
| Boudin, G | 1 |
| Guillard, A | 1 |
| Pépin, B | 1 |
| Castaigne, P | 2 |
| Laplane, D | 1 |
| Dordain, G | 1 |
| Hyyppä, M | 1 |
| Hacohen, H | 1 |
| Gurtner, B | 1 |
| Jameson, HD | 1 |
| Critchley, E | 2 |
| Musiol, A | 1 |
| Völler, G | 1 |
| Streifler, M | 1 |
| Kallay, U | 1 |
| Pigneri, MT | 2 |
| Rondot, P | 1 |
| Ribadeau-Dumas, JL | 1 |
| Ferel, D | 1 |
| Vecchi, L | 1 |
| Nagaswami, S | 1 |
| Ranjini, R | 1 |
| Korten, JJ | 1 |
| Dalle Ore, G | 1 |
| Buffatti, P | 1 |
| Bazzan, A | 1 |
| Mazza, C | 1 |
| Beani, L | 1 |
| Bianchi, C | 1 |
| Gomirato, G | 1 |
| Perfetti, C | 1 |
| Cartei, M | 1 |
| D'Andrea, F | 3 |
| De Divitiis, E | 3 |
| Signorelli, CD | 3 |
| Cerillo, A | 3 |
| Montanari, M | 1 |
| Monaco, V | 1 |
| Robotti, CA | 1 |
| Ferrari, W | 1 |
| Rossini, R | 1 |
| Bonasegla, F | 1 |
| Boncinelli, A | 1 |
| Prandi, G | 1 |
| Greggia, A | 1 |
| Crudeli, R | 1 |
| Candia, O | 1 |
| Rovetta, P | 1 |
| Fasano, VA | 2 |
| Urciuoli, R | 2 |
| Broggi, G | 2 |
| Ferraris, M | 1 |
| Buscaino, GA | 1 |
| Zallone, E | 1 |
| Barone, A | 1 |
| Gentile, A | 1 |
| Scoleri, G | 1 |
| Vitetta, M | 1 |
| Laterza, A | 1 |
| Jandolo, B | 1 |
| Sinibaldi, L | 1 |
| Volante, F | 1 |
| Accornero, N | 1 |
| Caliri, F | 1 |
| Meduri, M | 1 |
| Megna, G | 1 |
| Musolino, R | 1 |
| Scuderi, D | 1 |
| Barbieri, NF | 1 |
| Micalizzi, V | 1 |
| Ferro-Milone, F | 1 |
| Parisen-Toldin, P | 1 |
| Kluzer, G | 1 |
| Lampo, B | 1 |
| Ambrosetto, C | 1 |
| Martinelli, P | 1 |
| Antonini, FM | 1 |
| Baroni, A | 1 |
| Raspa, EG | 1 |
| Paciaroni, E | 1 |
| Saccomanno, G | 1 |
| Reitano, N | 1 |
| Schott, B | 2 |
| Griffiths, AV | 1 |
| Parker, WN | 1 |
| Palmer, RM | 1 |
| Marchoul, JC | 1 |
| Lapière, CM | 1 |
| Hartmann-von Monakow, K | 1 |
| Farnebo, LO | 1 |
| Fuxe, K | 1 |
| Goldstein, M | 1 |
| Hamberger, B | 1 |
| Ungerstedt, U | 1 |
| Penders, CA | 1 |
| Lutz, EG | 1 |
| Ebeling, P | 1 |
| Tubaro, E | 1 |
| Grelak, RP | 1 |
| Clark, R | 1 |
| Stump, JM | 1 |
| Vernier, VG | 1 |
| Green, J | 1 |
| Flatberg, P | 1 |
| Getz, R | 1 |
| Mercier, D | 1 |
| Schwieger, AC | 1 |
| Jenkins, AC | 1 |
| Morgan, L | 1 |
| Fernández Martín, F | 1 |
| Scatton, B | 1 |
| Cheramy, A | 1 |
| Besson, MJ | 1 |
| Glowinski, J | 1 |
| Grünberger, J | 2 |
| Oberhummer, I | 2 |
| Portera, A | 1 |
| Varela de Seijas, E | 1 |
| Mata, P | 1 |
| Ramírez Echevarría, TJ | 1 |
| Amaya Pombo, C | 1 |
| Waltregny, A | 1 |
| Kapp, W | 1 |
| Serratrice, G | 1 |
| Vollum, DI | 1 |
| Doyle, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)[NCT02136914] | Phase 3 | 126 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)[NCT02274766] | Phase 3 | 77 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients[NCT05479032] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy[NCT01313819] | Phase 4 | 20 participants (Anticipated) | Interventional | 2011-04-30 | Recruiting | ||
| Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease[NCT00794313] | 3 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to Funding Ended) | |||
| Experimentally-induced Freezing of Gait in Parkinson's Disease by Modulating Step Length/Asymmetry and Cognitive/Visual Loading[NCT04799613] | 20 participants (Anticipated) | Interventional | 2021-03-15 | Not yet recruiting | |||
| Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study[NCT00086307] | Phase 2 | 39 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| Urinary Excretion of Acetylamantadine by Cancer Patients[NCT02277938] | 120 participants (Anticipated) | Observational | 2013-08-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -8.0 |
| ADS-5102 (340 mg) | -15.9 |
The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -6.3 |
| ADS-5102 (340 mg) | -15.6 |
The MDS-UPDRS Parts I, II, and III examined non-motor experiences of daily living, motor experiences of daily living, and motor examination, respectively. Each Part contains items or questions that were each rated on a scale from 0 (normal) to 4 (severe). The Combined Parts I, II, and III (representing the sum of the individual scores from Parts I, II, and III) has a scale range of 0-236. Higher scores, whether for individual Parts or the sum of the combined Parts, indicate more severe PD. (NCT02136914)
Timeframe: Baseline (BL) to Week 12 (W12) and Week 24 (W24)
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Change from BL at Week 12 | Change from BL at Week 24 | |
| ADS-5102 (340 mg) | -5.2 | -1.3 |
| Placebo | -4.0 | -3.5 |
A PD home diary was used to score 5 different conditions in 30-minute intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 2, 8, 12, 18, and 24 visits. (NCT02136914)
Timeframe: Baseline (BL) to Week 12 (W12) and Week 24 (W24)
| Intervention | hours (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Change in ON time w/o troublesome dyskinesia (W12) | Change in ON time w/o troublesome dyskinesia (W24) | Change in OFF time (W12) | Change in OFF time (W24) | Change in ON time w/ troublesome dyskinesia (W12) | Change in ON time w/ troublesome dyskinesia (W24) | |
| ADS-5102 (340 mg) | 3.56 | 3.59 | -0.59 | -0.58 | -3.12 | -3.31 |
| Placebo | 0.82 | 1.37 | 0.32 | 0.22 | -1.58 | -1.86 |
The CGI-C consisted of a single question that assessed the investigator's global impression of the subject's change from Baseline in overall PD symptoms, including but not limited to LID. The CGI-C required that the investigator rate the extent to which the subject's PD had improved or worsened (from marked worsening to marked improvement). The CGI-C was assessed at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 12 and Week 24
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1271965983 | Week 1271965984 | Week 2471965984 | Week 2471965983 | |||||||||||||||||||||||||
| Moderate Improvement | Minimal Improvement | No Change | Minimal Worsening | Moderate Worsening | Marked Worsening | Marked Improvement | ||||||||||||||||||||||
| Placebo | 2 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 18 | |||||||||||||||||||||||||||
| Placebo | 9 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 20 | |||||||||||||||||||||||||||
| Placebo | 10 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 13 | |||||||||||||||||||||||||||
| Placebo | 25 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 9 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 2 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 0 | |||||||||||||||||||||||||||
| Placebo | 0 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 1 | |||||||||||||||||||||||||||
| Placebo | 5 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 14 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 17 | |||||||||||||||||||||||||||
| Placebo | 12 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 12 | |||||||||||||||||||||||||||
| Placebo | 17 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 7 | |||||||||||||||||||||||||||
| Placebo | 6 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 5 | |||||||||||||||||||||||||||
| Placebo | 4 | |||||||||||||||||||||||||||
The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 4, 8, and 12. (NCT02274766)
Timeframe: Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -6.3 |
| ADS-5102 (Amantadine HCl Extended Release) | -20.7 |
A PD home diary was used to score 5 different conditions in 30-minute intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 2, 4, 8, and 12 visits. (NCT02274766)
Timeframe: Baseline to Week 12
| Intervention | hours (Least Squares Mean) | ||
|---|---|---|---|
| Change in ON time without troublesome dyskinesia | Change in ON time with troublesome dyskinesia | Change in OFF time | |
| ADS-5102 (Amantadine HCl Extended Release) | 3.95 | -3.61 | -0.49 |
| Placebo | 2.05 | -2.47 | 0.61 |
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
Area under the curve for the root mean squared velocity in the anterior-posterior direction as measured by a forceplate. (NCT00794313)
Timeframe: Every 1/2 hour for 8 hour levodopa cycle
| Intervention | (meters/second)*hours (Mean) |
|---|---|
| Amantadine | 10.4 |
| Amantadine Plus Topiramate | 9.4 |
| Sugar Pill | 19.1 |
Area under the curve computed for whole body (total) mAIMS (Modified Abnormal Involuntary Movement Scale) scores at each time measurement. This is a commonly utilized scale that is completed by an observer who judges the severity of levodopa induced dyskinesia (LID) in 7 body parts (face, neck, trunk, both legs, and both arms). All body parts are rated separately on this 0 (none) to 4 (severe - markedly impairs activities) scale. Thus, the total score can range from 0 - 28 with 28 indicating the most severe LID. mAIMS ratings occur as the subject performs the cognitive task while standing on the force plate. mAIMS ratings are made every half hour during the levodopa (LD) dose cycle. (NCT00794313)
Timeframe: Measured every 1/2 hour for a levodopa dose cycle (starting 1 hour prior to infusion and ending 4 hours post 2-hour infusion)
| Intervention | Units on a Scale * Hours (Mean) |
|---|---|
| Amantadine | 4.0 |
| Amantadine Plus Topiramate | 5.3 |
| Sugar Pill | 8.5 |
The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 item scale for assessing the severity of depression. Items are rated on a scale of 0 to 6, so the maximum score is 60 and the minimum is 0, where 60 is the most severe depression. Scores of 18 or greater are generally considered to indicate a moderate level of depression. (NCT00086307)
Timeframe: Weekly
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Pramipexole | 22.629 |
| Escitalopram | 26.102 |
| Escitalopram and Pramipexole | 29.455 |
111 reviews available for amantadine and Parkinson Disease
| Article | Year |
|---|---|
Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
Topics: Amantadine; Animals; Antiparkinson Agents; Confusion; Delayed-Action Preparations; Dopamine; Drug Th | 2021 |
Amantadine in the treatment of Parkinson's disease and other movement disorders.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
GOCOVRI
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase; Delayed-Action Preparations; Dyskine | 2022 |
Metabotropic glutamate receptors in Parkinson's disease.
Topics: Amantadine; Glutamates; Humans; Parkinson Disease; Receptors, Metabotropic Glutamate | 2023 |
Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Bias; Constipation; Del | 2019 |
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Development; Drug Repositioning; Dyskinesia, Drug-In | 2020 |
Amantadine Associated Myoclonus: Case Report and Review of the Literature.
Topics: Aged, 80 and over; Amantadine; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease | 2021 |
Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.
Topics: Amantadine; Diamond; Humans; Huntington Disease; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2021 |
Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature.
Topics: Aged; Amantadine; Antiparkinson Agents; Female; Humans; Neuroleptic Malignant Syndrome; Parkinson Di | 2021 |
Implications of dopaminergic medication withdrawal in Parkinson's disease.
Topics: Amantadine; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Substance Withdrawal S | 2022 |
Parkinson's disease and pregnancy: An updated review.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Female; Humans; Levodopa; Parkinson Disea | 2017 |
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug- | 2018 |
Amantadine Extended-Release (GOCOVRI
Topics: Amantadine; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, | 2018 |
Meta-analysis of amantadine efficacy for improving preclinical research reliability.
Topics: Amantadine; Animals; Databases, Bibliographic; Dopamine Agents; Drug Evaluation, Preclinical; Humans | 2018 |
Osmolex ER--another extended-release amantadine for Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agonists; Humans; P | 2018 |
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Delayed-Action Preparations; Dyskinesia, Drug-In | 2019 |
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O- | 2014 |
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Sched | 2014 |
Current treatment and future prospects of dopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship | 2015 |
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
Topics: Amantadine; Anti-Dyskinesia Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; P | 2016 |
[Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Topics: Amantadine; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa | 2017 |
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoami | 2010 |
Milestones in Parkinson's disease therapeutics.
Topics: Amantadine; Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agents; Enzyme Inhibitors; Histor | 2011 |
Molecular mechanisms of l-DOPA-induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Genes, Immediate | 2011 |
Updates in the medical management of Parkinson disease.
Topics: Age Factors; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Cholinergi | 2012 |
Amantadine: the journey from fighting flu to treating Parkinson disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Antiviral Agents; Humans; Influenza, Human; Parkinson Dis | 2012 |
N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.
Topics: Amantadine; Databases, Factual; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced | 2012 |
Amantadine and other antiglutamate agents: management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Glutamic Acid; Humans; Parkinson Disease; Psychomotor Performance; | 2002 |
Renaissance of amantadine in the treatment of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Glut | 2003 |
Practical importance of neuroprotection in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Indoles; Neuroprotective Agents; Parkin | 2002 |
Amantadine in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials | 2003 |
Amantadine for dyskinesia in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dyskinesias; Humans; Parkinson Disease; Randomized Controlled Tria | 2003 |
Rationale for current therapies in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inh | 2003 |
[Treatment of Parkinson disease in patients with surgical problems].
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Health Status; Humans; Levodopa; Parkinson Disease; P | 2003 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergo | 2005 |
Other pharmacological treatments for motor complications and dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskin | 2005 |
Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Human | 2005 |
Parkinson disease: managing a complex, progressive disease at all stages.
Topics: Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Gait; Humans; Levodopa; Pa | 2007 |
[Diagnosis and treatment of tremor in Parkinson's disease and essential tremor].
Topics: Adrenergic beta-Antagonists; Amantadine; Anticonvulsants; Antiparkinson Agents; Deep Brain Stimulati | 2007 |
Pharmacotherapy for Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; | 2007 |
Update on antiparkinsonian agents.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationsh | 1982 |
[Biochemical bases of Parkinson disease].
Topics: Acetylcholine; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dopa Decarboxylase; | 1984 |
Pharmacology of Parkinson's disease.
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Biopterins; Dopamine; Histamine H1 Antagoni | 1984 |
Anti-parkinsonian drugs today.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Brain Chemistry; Catechol O-Methyltransferase Inhibi | 1984 |
[Antiparkinsonian drugs (author's transl)].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibit | 1980 |
The management of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; H | 1982 |
Parkinson's disease: managing symptoms and preserving function.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Delayed-Action Preparations; Drug Combina | 1995 |
Drug treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Cholinergic Agents; Dopamine Agonists; Humans; | 1995 |
[Chemotherapy of Parkinson disease with agents other than L-DOPA or dopamine agonists].
Topics: Amantadine; Cholinergic Antagonists; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease | 1994 |
Treatment options for early Parkinson's disease.
Topics: Algorithms; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine | 1996 |
Drug management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Selegiline; Tr | 1996 |
Twenty-five years of amantadine therapy in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, D | 1995 |
Amantadine in Parkinson's disease: pro and contra.
Topics: Amantadine; Antiparkinson Agents; Contraindications; Excitatory Amino Acid Antagonists; Humans; Park | 1995 |
[New therapeutic strategy for Parkinson's disease based on pharmacological profiles].
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Dru | 1997 |
[Treatment of Parkinson's disease with multiple drugs].
Topics: Amantadine; Bromocriptine; Cholinergic Antagonists; Dopamine Agonists; Drug Therapy, Combination; Hu | 1997 |
[Initial treatment of Parkinson's disease].
Topics: Amantadine; Antioxidants; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Di | 1997 |
Early idiopathic parkinsonism: initiation and optimization of treatment.
Topics: Amantadine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegil | 1994 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesi | 1997 |
Pregnancy in Parkinson's disease: a review of the literature and a case report.
Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agen | 1998 |
[Amantadine-induced livedo reticularis].
Topics: Adult; Amantadine; Drug Eruptions; Female; Humans; Lymphedema; Parkinson Disease; Skin Diseases, Vas | 1998 |
Initiating therapy for Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic An | 1998 |
[Drug therapy in Parkinson's disease].
Topics: Amantadine; Antiparkinson Agents; Clozapine; Dopamine Agonists; Dopamine Antagonists; Female; Histor | 1999 |
Possible use of amantadine in depression.
Topics: Amantadine; Animals; Antidepressive Agents; Depression; Depressive Disorder; Dopamine Agents; Humans | 1999 |
Transient benefit of amantadine in Parkinson's disease: the facts about the myth.
Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Double-Blind Method; Humans; Parkinson Disease; Tr | 1999 |
Medical treatment of levodopa-induced dyskinesias.
Topics: Amantadine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Tremor-predominant Parkinson's disease. Approaches to treatment.
Topics: Acetates; Amantadine; Amines; Antiparkinson Agents; Botulinum Toxins; Cholinergic Antagonists; Clona | 2000 |
[What strategies are recommended for early stage disease? Other treatments].
Topics: Amantadine; Antioxidants; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic | 2000 |
Pharmacological treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Diag | 2000 |
[Pharmacological treatments of Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenon | 2001 |
[Parkinson disease: diagnostic and therapeutic criteria].
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, | 2001 |
Parkinson's disease: medical treatment of moderate to advanced disease.
Topics: Amantadine; Anti-Anxiety Agents; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; | 2002 |
[Considerations in the drug treatment of parkinsonism (author's transl)].
Topics: Amantadine; Apomorphine; Bromocriptine; Dopamine; Ergolines; Extrapyramidal Tracts; Female; Humans; | 1978 |
[Therapy of tparkinson's disease. Clinical and pharmacological viewpoints].
Topics: Adrenergic beta-Antagonists; Amantadine; Bromocriptine; Histamine H1 Antagonists; Humans; Levodopa; | 1979 |
[Iatrogenic damage possibilities in the drug therapy of neurologic and psychiatric diseases].
Topics: Amantadine; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Central Nervous System Di | 1977 |
Considerations in the management of parkinsonism.
Topics: Amantadine; Carboxy-Lyases; Levodopa; Parasympatholytics; Parkinson Disease | 1978 |
Drug therapy: Bromocriptine.
Topics: Acromegaly; Adenoma; Amantadine; Bromocriptine; Female; Galactorrhea; Growth Hormone; Humans; Infert | 1979 |
Treatment of parkinsonism.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Drug Therapy, Combination; Humans; Levodop | 1976 |
Advances in the management of parkinson's disease.
Topics: Amantadine; Anesthesia; Humans; Levodopa; Orphenadrine; Parasympatholytics; Parkinson Disease; Socia | 1976 |
[The current treatment of Parkinson's disease].
Topics: Amantadine; Antidepressive Agents, Tricyclic; Dihydroxyphenylalanine; Drug Combinations; Histamine A | 1976 |
Initiating treatment of Parkinson's disease.
Topics: Amantadine; Antioxidants; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; | 1992 |
Recent progress in the treatment of Parkinson's disease.
Topics: Amantadine; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1992 |
Drug therapy for Parkinson's disease in the elderly.
Topics: Aged; Amantadine; Antiparkinson Agents; Carboxy-Lyases; Dopamine Antagonists; Humans; Levodopa; Para | 1990 |
Amantadine hydrochloride: current and new uses.
Topics: Amantadine; Humans; Influenza, Human; Multiple Sclerosis; Parkinson Disease | 1990 |
Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
Topics: Amantadine; Antiparkinson Agents; Atrophy; Brain; Bromocriptine; Cognition; Dementia; Dreams; Drug I | 1986 |
[Parkinson disease. The clinical picture and therapy].
Topics: Adrenergic beta-Antagonists; Amantadine; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibito | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Clinical pharmacokinetics of amantadine hydrochloride.
Topics: Administration, Inhalation; Administration, Oral; Age Factors; Amantadine; Drug Interactions; Humans | 1988 |
Parkinson's disease in the elderly: psychiatric manifestations.
Topics: Aged; Amantadine; Depression; Humans; Levodopa; Mood Disorders; Parasympatholytics; Parkinson Diseas | 1985 |
Update on the treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinso | 1985 |
Amantadine.
Topics: Acetylcholine; Amantadine; Animals; Antiviral Agents; Basal Ganglia Diseases; Behavior, Animal; Cate | 1974 |
Theoretical implications of the use of L-dopa in parkinsonism. A review.
Topics: Acetylcholine; Amantadine; Animals; Cats; Dihydroxyphenylalanine; Dopamine; Female; Haplorhini; Huma | 1970 |
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia Diseases; Brain Che | 1971 |
[Biochemical aspects of human behavior].
Topics: Amantadine; Behavior; Biogenic Amines; Brain; Depression; Dihydroxyphenylalanine; Dopamine; Epinephr | 1973 |
Parkinson's syndrome. Recent progress in the medical treatment and its pharmacological basis.
Topics: Amantadine; Atropine; Catecholamines; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Imip | 1971 |
[Recent advances and pharmacological basis of the medical treatment of Parkinson's syndrome].
Topics: Amantadine; Catecholamines; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Imipramine; Pa | 1971 |
Drug therapy of parkinsonism.
Topics: Amantadine; Amitriptyline; Amphetamine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Antagonis | 1972 |
The management of Parkinson's syndrome.
Topics: Adult; Aged; Amantadine; Benztropine; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Female; Huma | 1972 |
Parkinsonism, levodopa, and anesthesia.
Topics: Amantadine; Anesthesia; Animals; Apomorphine; Benperidol; Blood-Brain Barrier; Brain; Cardiovascular | 1972 |
Advances in geriatrics.
Topics: Aged; Amantadine; Diet Therapy; Dihydroxyphenylalanine; Diverticulum, Colon; Drug-Related Side Effec | 1972 |
[Parkinsonism. Therapeutic, pathophysiological, pharmacological and biochemical aspects].
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Central Nervous System; Dihydroxyphenylala | 1973 |
Augmenting the action of levodopa.
Topics: Amantadine; Antacids; Apomorphine; Carboxy-Lyases; Catechol O-Methyltransferase Inhibitors; Dihydrox | 1972 |
[Review of current pharmacotherapy of Parkinsonism. Comprehensive review].
Topics: 5-Hydroxytryptophan; Amantadine; Anticonvulsants; Apomorphine; Benztropine; Carboxy-Lyases; Chemical | 1973 |
Parkinson's disease; modern treatment.
Topics: Amantadine; Amphetamine; Antidepressive Agents; Antiparkinson Agents; Aromatic Amino Acid Decarboxyl | 1973 |
Recent advances in the treatment of Parkinsonism with drugs.
Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Arrhythmias, Cardiac; Blood-Brain | 1972 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
Individualization of levodopa therapy.
Topics: Amantadine; Amphetamine; Anesthetics; Animals; Antihypertensive Agents; Apomorphine; Arrhythmias, Ca | 1974 |
[Therapy of Parkinsonism. II].
Topics: Amantadine; Amitriptyline; Humans; Imipramine; Levodopa; Parkinson Disease; Physical Therapy Modalit | 1974 |
Use of drugs in the treatment of parkinsonism.
Topics: Amantadine; Depression; Dihydroxyphenylalanine; Feeding and Eating Disorders; Humans; Hypertension; | 1970 |
[Therapy and problems of parkinsonism].
Topics: Adult; Aged; Amantadine; Animals; Antidepressive Agents; Apomorphine; Brain Chemistry; Brain Stem; D | 1971 |
Current concepts of Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parasympatholytics; Parkinson Disease; Stereotaxic Techn | 1971 |
122 trials available for amantadine and Parkinson Disease
| Article | Year |
|---|---|
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Topics: Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; P | 2022 |
Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study.
Topics: Aged; Amantadine; Antiparkinson Agents; Drug Administration Schedule; Dyskinesias; Female; Humans; I | 2019 |
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Topics: Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Hu | 2020 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug | 2017 |
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
Topics: Amantadine; Anticonvulsants; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2017 |
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Doubl | 2017 |
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Capsules; Delayed-Action Preparati | 2018 |
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Capsules; Delayed-Action Preparati | 2018 |
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Capsules; Delayed-Action Preparati | 2018 |
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Capsules; Delayed-Action Preparati | 2018 |
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cross-Over Studies; De | 2019 |
Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dys | 2019 |
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Doubl | 2019 |
Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Gait; Gait Disorders, Neurologic; Human | 2013 |
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2014 |
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dose- | 2015 |
[Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole].
Topics: Aged; Amantadine; Benzothiazoles; Depressive Disorder, Major; Dopamine Agonists; Drug Therapy, Combi | 2008 |
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, D | 2010 |
Pathological gambling in Parkinson disease is reduced by amantadine.
Topics: Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Female; Follow-Up S | 2010 |
Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesias; | 2010 |
Effect of intravenous amantadine on dopaminergic-drug-resistant freezing of gait.
Topics: Aged; Amantadine; Antiparkinson Agents; Gait Disorders, Neurologic; Humans; Infusions, Intravenous; | 2011 |
Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Cross-Over Studies; Dopamine; Double-Blind Method; Drug | 2012 |
Amantadine improves gait in PD patients with STN stimulation.
Topics: Adult; Amantadine; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Female; | 2013 |
Which dyskinesia scale best detects treatment response?
Topics: Aged; Amantadine; Analysis of Variance; Antiparkinson Agents; Dose-Response Relationship, Drug; Doub | 2013 |
New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study.
Topics: Aged; Amantadine; Antiparkinson Agents; Brain Chemistry; Caudate Nucleus; Dopamine Antagonists; Fema | 2002 |
Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Female; Humans; Infusions, Intravenous; Male; Middle Aged; M | 2003 |
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
Topics: Aged; Amantadine; Dopamine Agents; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; | 2004 |
Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
Topics: Aged; Amantadine; Antiparkinson Agents; Edema; Female; Humans; Middle Aged; Motor Activity; Parkinso | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2005 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Com | 2006 |
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Arm; Benzothiazoles; Biomechanic | 2006 |
Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Administration Routes; Drug A | 2007 |
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Disability Evaluation; Disease Progression; Double-Blind Met | 2007 |
[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].
Topics: Administration, Oral; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Memantine; M | 1984 |
[The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
Topics: Adult; Amantadine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Ma | 1981 |
Weekly drug holiday in Parkinson disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; D | 1981 |
Latency and successive reaction time in Parkinson's disease--the effects of carbidopa and amantadine.
Topics: Amantadine; Carbidopa; Humans; Parkinson Disease; Reaction Time | 1981 |
[Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
Topics: Amantadine; Amino Acids; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Piperidines | 1980 |
Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Capsules; Evaluation Studies as Topic; Femal | 1995 |
New lessons from old drugs: amantadine and Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Cross-Over Studies; Humans; Parkinson Disease | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, | 1998 |
Transient benefit of amantadine in Parkinson's disease: the facts about the myth.
Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Double-Blind Method; Humans; Parkinson Disease; Tr | 1999 |
Effects of amantadine treatment on in vitro production of interleukin-2 in de-novo patients with idiopathic Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Dopamine Agents; Female; Humans; Interferon-gamma; Inter | 1999 |
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-In | 2000 |
Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, | 2000 |
[Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Double-Blind Method; Female; Humans; Male | 2001 |
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Drug Therapy, Combinat | 2001 |
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedu | 2001 |
The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Asian People; Black or African American; | 2002 |
Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combina | 1977 |
[Effects of intravenous administration of memantine in parkinsonian patients (author's transl)].
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Infusions, Parenteral; Male; Mema | 1977 |
Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Bromocriptine; Chorea; Clinical Trials as Topic; Depressio | 1978 |
Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; F | 1978 |
Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; | 1976 |
[Clinical experience with bromocriptine, a central dopaminergic stimulator].
Topics: Aged; Amantadine; Bromocriptine; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Respo | 1976 |
The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Evaluation; Drug Therapy, Com | 1976 |
Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up.
Topics: Activities of Daily Living; Aged; Amantadine; Benztropine; Clinical Trials as Topic; Diphenhydramine | 1975 |
Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Huma | 1975 |
Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; | 1976 |
Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.
Topics: Activities of Daily Living; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Disability | 1975 |
Amphetamines in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Amphetamine; Clinical Trials as Topic; Female; Humans; Isomerism; Levodopa; Male; | 1975 |
Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Huma | 1975 |
The treatment with L-dopa and amantadine in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Levodopa; Male; Middle Aged; Park | 1975 |
The effect of Dopaflex and Viregyt-K on gait and postural disturbances of operated and non-operated Parkinsonian patients.
Topics: Amantadine; Clinical Trials as Topic; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Postur | 1975 |
[Modification of Parkinson tremor by budipine. A comparative study with amantadine].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Clinical Trials as Topic; Double-Blind Method; Drug T | 1986 |
Amantadine in migraine.
Topics: Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Migraine Disorders; Parkinson | 1972 |
Effect of L-dopa or amantadine therapy on sleep spindles in Parkinsonism.
Topics: Action Potentials; Adult; Aged; Amantadine; Dihydroxyphenylalanine; Electroencephalography; Electrom | 1973 |
Controlled trial of amantadine hydrochloride in Parkinson's disease.
Topics: Aged; Amantadine; Chlorides; Clinical Trials as Topic; Humans; Middle Aged; Motor Activity; Movement | 1970 |
Amantadine for Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Parkinson Disease; Placebos | 1970 |
Amantadine in parkinsonism.
Topics: Aged; Amantadine; Chlorides; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Parkinson | 1970 |
Amantadine dosage in treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Female; Humans; Male; Middle Aged; Parkinson Disease; Sex Factors | 1970 |
Amantadine versus L-2 dopa and amatadine plus L-dopa.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1970 |
Combined treatment of parkinsonism with L-dopa and amantadine.
Topics: Aged; Amantadine; Chorea; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Humans; Hypotens | 1970 |
Combined treatment of parkinsonism with L-dopa and amantadine.
Topics: Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Parkinson Disease; Placebos | 1970 |
Treatment of Parkinsonism with L-dopa and amantadine.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Placebos | 1970 |
A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).
Topics: Adult; Amantadine; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Female; Humans; Ma | 1973 |
Administration of amandine to patients on optimum L-dopa dosage.
Topics: Amantadine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Parkin | 1972 |
Amantadine therapy in parkinsonism.
Topics: Age Factors; Aged; Amantadine; Clinical Trials as Topic; Edema; Electrocardiography; Female; Follow- | 1972 |
Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism.
Topics: Amantadine; Clinical Trials as Topic; Humans; Movement Disorders; Parkinson Disease; Placebos | 1972 |
Trial of amantadine in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Constipation; Female; Hallucinations; Handwriting | 1972 |
A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease.
Topics: Activities of Daily Living; Aged; Amantadine; Clinical Trials as Topic; Feeding Behavior; Female; Ga | 1972 |
Treatment of Parkinson's disease with amantadine and L-Dopa.
Topics: Adult; Aged; Alkaline Phosphatase; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Dru | 1972 |
The comparative value of amantadine and levodopa.
Topics: Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Middle Aged; Parkinson Disease | 1972 |
Combined L-dopa and amantadine in Parkinsonism.
Topics: Aged; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; | 1972 |
[Clinical evaluation of the drugs and quantitative nosography].
Topics: Amantadine; Biopharmaceutics; Clinical Trials as Topic; Dihydroxyphenylalanine; Evaluation Studies a | 1972 |
[Treatment of Parkinson's disease with amantadine].
Topics: Administration, Oral; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Synergism; | 1972 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
[Amantadine therapy in Parkinsonism].
Topics: Amantadine; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Male; Parasympatholytics; P | 1972 |
The effect of adding amantadine to optimum L-dopa dosage in Parkinson's syndrome.
Topics: Aged; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; | 1973 |
Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa.
Topics: Activities of Daily Living; Aged; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Eval | 1973 |
[Therapeutic experiences with amantadine sulfate as a monotherapeutic drug in patients with Parkinsonism].
Topics: Adult; Aged; Amantadine; Animals; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; M | 1973 |
[Amantadine and dexetimide in the treatment of parkinsonism].
Topics: Administration, Oral; Adult; Aged; Amantadine; Benzyl Compounds; Clinical Trials as Topic; Delayed-A | 1973 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
KR 339 in the treatment of Parkinsonian tremor.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood Sedimentation; Bridged-Ring Compounds; Clinical Trials | 1974 |
[Kr 339 in the treatment of parkinsonian tremor].
Topics: Aged; Amantadine; Antiparkinson Agents; Bridged-Ring Compounds; Clinical Trials as Topic; Dihydroxyp | 1974 |
A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Benztropine; Capsules; Chlorpromazine; Clini | 1974 |
Refinement in the measurement of treatment response with combined L-dopa and amantadine in Parkinsonism.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Female; Human | 1974 |
[Efficacy of amantadine sulfate as a infusion solution in the treatment of parkinsonian syndrome].
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Infusions, Paren | 1973 |
Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Drug Combinations; Female; Humans; Levodopa; Male | 1974 |
An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used incombination in Parkinson's Disease.
Topics: Amantadine; Clinical Trials as Topic; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged | 1974 |
[Principles for amantadine therapy in parkinsonism].
Topics: Amantadine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Humans; Parkinson Disease; Pla | 1972 |
[Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes].
Topics: Amantadine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Combinations; Drug Synergism; Humans; | 1972 |
Livedo reticularis in Parkinson's disease patients treated with amantadine hydrochloride.
Topics: Aged; Amantadine; Cold Temperature; Edema; Evaluation Studies as Topic; Female; Humans; Male; Middle | 1972 |
[The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].
Topics: Adult; Aged; Amantadine; Chronic Disease; Female; Humans; Male; Middle Aged; Parasympatholytics; Par | 1973 |
Parkinson disease treated with a suspected dopamine receptor agonist.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Dihydroxyphenyla | 1974 |
Comparison of amantadine, placebo, and levodopa in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; Humans; Male; Middle | 1974 |
L-dopa and amantadine in the therapy of parkinsonism.
Topics: Aged; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Synergism; Drug Tolerance; | 1969 |
Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Humans; Male; Middle Age | 1969 |
Amantadine treatment of Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Humans; Parkinson Disease; Placebos | 1970 |
Use of amantadine in Parkinson's disease. Results of a double-blind trial.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Parkinson Dise | 1970 |
Amantadine hydrochloride in the treatment of Parkinsonism. A controlled trial.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Analysis of Variance; Clinical Trials as Topic; | 1970 |
Amantadine hydrochloride in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Headache; Humans; Male; Middle Aged; Naus | 1970 |
[Amantadine treatment in Parkinson's disease].
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Parkinson Dise | 1970 |
Amantadine in Parkinsonism. An extended prospective trial.
Topics: Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Movement; Parkinson D | 1971 |
L-dopa and amantadine hydrochloride in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evaluation; Fe | 1971 |
[Results of two new drugs in Parkinson's disease: L-dopa and amantadine].
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Middle Aged; Park | 1970 |
Controlled trial of amantadine hydrochloride in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Humans; Hydr | 1971 |
Amantadine hydrochloride in the treatment of parkinsonism: a placebo-controlled double-blind study.
Topics: Aged; Amantadine; Clinical Trials as Topic; Female; Gait; Humans; Jaw; Male; Middle Aged; Parkinson | 1971 |
Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.
Topics: Age Factors; Alkaline Phosphatase; Amantadine; Blood Glucose; Blood Urea Nitrogen; Clinical Trials a | 1971 |
Amantadine for Parkinson's disease.
Topics: Aged; Amantadine; Amines; Brain; Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evalua | 1971 |
Effect of amantadine on some psychomotor performances in Parkinsonism. A double blind study.
Topics: Adult; Aged; Amantadine; Arm; Clinical Trials as Topic; Female; Hand; Humans; Male; Middle Aged; Mot | 1971 |
The continued use of amantadine hydrochloride in parkinsonism.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Hydrochloric A | 1971 |
Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Evaluation Studies as Topic; Humans; Middle Aged; Parkinson Di | 1971 |
Experiences with amantadine hydrochloride in Parkinson's disease.
Topics: Aged; Amantadine; Humans; Male; Middle Aged; Parkinson Disease; Placebos | 1971 |
[The effect of amantadine in parkinsonism: clinical and neurophysiological findings].
Topics: Adult; Aged; Amantadine; Electroencephalography; Humans; Middle Aged; Parkinson Disease | 1970 |
409 other studies available for amantadine and Parkinson Disease
| Article | Year |
|---|---|
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
Topics: Amines; Animals; Antiparkinson Agents; Cells, Cultured; Humans; Memantine; Molecular Structure; Neur | 2010 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; | 2014 |
Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Ret | 2022 |
Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson's Disease in Rats.
Topics: Acetylcholinesterase; Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Male; Model | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitat | 2022 |
Amantadine therapy for Parkinson's Disease: In Vivo Confocal Microscopy corneal findings, case report and revision of literature.
Topics: Aged; Amantadine; Corneal Edema; Endothelial Cells; Humans; Male; Microscopy, Confocal; Parkinson Di | 2022 |
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Pain; Parkinson Diseas | 2022 |
Anticancer Activity of Amantadine and Evaluation of Its Interactions with Selected Cytostatics in Relation to Human Melanoma Cells.
Topics: Amantadine; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Humans; M | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidin | 2022 |
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study.
Topics: Aged; Amantadine; Cohort Studies; COVID-19; Humans; Male; Middle Aged; Morbidity; Parkinson Disease; | 2023 |
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study.
Topics: Aged; Amantadine; Cohort Studies; COVID-19; Humans; Male; Middle Aged; Morbidity; Parkinson Disease; | 2023 |
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study.
Topics: Aged; Amantadine; Cohort Studies; COVID-19; Humans; Male; Middle Aged; Morbidity; Parkinson Disease; | 2023 |
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study.
Topics: Aged; Amantadine; Cohort Studies; COVID-19; Humans; Male; Middle Aged; Morbidity; Parkinson Disease; | 2023 |
Time until modification of antiparkinsonian therapy in a group of patients from Colombia.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Colombia; Female; Humans; Levodopa; Male; | 2023 |
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome?
Topics: Alzheimer Disease; Amantadine; COVID-19; Humans; Memantine; Parkinson Disease; Post-Acute COVID-19 S | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Ind | 2023 |
Amantadine withdrawal in a patient with spinocerebellar ataxia.
Topics: Amantadine; Deglutition Disorders; Humans; Male; Parkinson Disease; Spinocerebellar Ataxias; Substan | 2023 |
Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.
Topics: Amantadine; Animals; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyski | 2023 |
[Parkinson's Disease: amantadine, zonisamide, dabrafenib].
Topics: Amantadine; Antiparkinson Agents; Drug Repositioning; Genome-Wide Association Study; Humans; Imidazo | 2019 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Ne | 2020 |
Repeated Intravenous Amantadine Infusions in Advanced Parkinsonism: Experience of a Large Movement Disorder Center.
Topics: Accidental Falls; Aged; Amantadine; Disease Progression; Dopamine Agents; Dose-Response Relationship | 2019 |
A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy.
Topics: Aged; Amantadine; Antiparkinson Agents; Catechols; Dopamine Agonists; Drug Therapy, Combination; Fem | 2020 |
Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study.
Topics: Aged; Amantadine; Antiparkinson Agents; Deep Brain Stimulation; Delayed-Action Preparations; Female; | 2020 |
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, D | 2020 |
Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease.
Topics: Amantadine; Apomorphine; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Do | 2020 |
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug- | 2020 |
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Co | 2020 |
Amantadine for COVID-19.
Topics: Amantadine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Fatigue; Humans; Multiple Sclerosis | 2021 |
Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson's Disease.
Topics: Amantadine; Antiviral Agents; COVID-19 Drug Treatment; Humans; Pandemics; Parkinson Disease; Pharmac | 2022 |
[Amantadine in the treatment of Parkinson's disease. New opportunities in the context of COVID-19].
Topics: Amantadine; Antiparkinson Agents; COVID-19; Humans; Levodopa; Parkinson Disease; SARS-CoV-2 | 2021 |
Extended amantadine-induced livedo reticularis.
Topics: Amantadine; Humans; Livedo Reticularis; Parkinson Disease | 2021 |
Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost?
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dyskinesias; Humans; Levodopa; Parkin | 2017 |
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ma | 2018 |
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Drug Compounding; Dyskinesia, Drug-In | 2017 |
Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior Rating Scale; Behavior, Animal; Disease Models, | 2018 |
Corneal Evaluation in Patients With Parkinsonism on Long-Term Amantadine Therapy.
Topics: Aged; Amantadine; Antiparkinson Agents; Endothelial Cells; Endothelium, Corneal; Female; Humans; Lon | 2019 |
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levod | 2019 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse C | 2013 |
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans | 2014 |
Amantadine's role in the treatment of levodopa-induced dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Park | 2014 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Rout | 2014 |
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine A | 2014 |
Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
Topics: Amantadine; Antiparasitic Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa | 2014 |
Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Male; Parkinson Disease | 2014 |
Author response.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Male; Parkinson Disease | 2014 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, | 2016 |
Amantadine Use as a Risk Factor for Corneal Edema: A Nationwide Cohort Study in Taiwan.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Corn | 2016 |
Fatal intoxication using amantadine and pramipexole in a uremic patient.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Fatal Outcome; Female; Humans; Middle Aged; Parkin | 2008 |
Plasma amantadine concentrations in patients with Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Creatinine; Delirium; Female; Hallucinations; Humans; | 2009 |
Hiccups and dopamine.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dopamine Antagonists; Hiccup; H | 2008 |
Corneal endothelial dysfunction associated with amantadine toxicity.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Cell Count; Corneal Edema; Endothelium, Corn | 2008 |
Toxic corneal oedema associated with amantadine use.
Topics: Amantadine; Antiparkinson Agents; Child; Cornea; Corneal Edema; Female; Humans; Middle Aged; Parkins | 2009 |
Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Blood Platelets; Disease Progression; Female; Humans; | 2009 |
Medical treatment of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cognition Disorders; Corp | 2009 |
Sudden bilateral corneal oedema in a patient with Parkinson's disease.
Topics: Adult; Amantadine; Antiparkinson Agents; Blindness; Corneal Edema; Functional Laterality; Humans; Ma | 2011 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Lev | 2009 |
Room tilt illusion in Parkinson's disease: loss of spatial reference frames?
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Humans; Illusions; Levodopa; Male; Orientat | 2009 |
The effect of amantadine on corneal endothelium in subjects with Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cell Count; Corneal Diseases; Cross-Sectional Studies | 2010 |
[The use of antiparkinsonism drugs in 92 cases in Xi'an city].
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; China; Dopamine Agon | 2009 |
Simultaneous determination of memantine and amantadine in human plasma as fluorescein derivatives by micellar electrokinetic chromatography with laser-induced fluorescence detection and its clinical application.
Topics: Acetonitriles; Alzheimer Disease; Amantadine; Antiparkinson Agents; Chemical Fractionation; Chromato | 2010 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; | 2010 |
Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Female; Hallucinations; Humans; Music; Parkinson Disease | 2010 |
[The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Cognition Disorders; Female; Humans; Male; Middle Aged; Neur | 2010 |
Management of punding in Parkinson's disease: an open-label prospective study.
Topics: Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Levod | 2011 |
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.
Topics: Aged; Amantadine; Antiparkinson Agents; Cross-Sectional Studies; Disruptive, Impulse Control, and Co | 2010 |
Amantadine induced reversible corneal edema.
Topics: Amantadine; Antiparkinson Agents; Corneal Edema; Female; Humans; Iatrogenic Disease; Middle Aged; Pa | 2011 |
Is pathological gambling in Parkinson's disease reduced by amantadine?
Topics: Aged; Amantadine; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Female; | 2011 |
Intravenous amantadine is safe and effective for the perioperative management of patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Female; Humans; Male; Middle Aged; Parkin | 2011 |
Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Apoptosis; Brain; Cell Count; Dis | 2012 |
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dop | 2011 |
Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine.
Topics: Amantadine; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans | 2012 |
Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence.
Topics: Amantadine; Anesthesia; Anesthesia Recovery Period; Anesthesia, General; Antiparkinson Agents; Carbi | 2011 |
Patient perception of Levido reticularis due to amantadine.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Female; Humans; Livedo Reticularis | 2012 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Dis | 2012 |
Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
Topics: Aged; Amantadine; Antidepressive Agents; Antiparkinson Agents; Data Collection; Depression; Disease | 2012 |
[Corneal toxicity due to amantadine].
Topics: Acyclovir; Amantadine; Antiparkinson Agents; Aqueous Humor; Cataract Extraction; Ceftazidime; Cornea | 2012 |
[Mexidant increases the effectiveness of levadopa treatment of Parkinson's disease].
Topics: Aged; Amantadine; Antioxidants; Antiparkinson Agents; Dopamine Agonists; Drug Administration Schedul | 2012 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agent | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
[The use of amantadine sulfate in combined therapy of Parkinson's disease].
Topics: Aged; Amantadine; Carbidopa; Dopamine Agents; Drug Combinations; Drug Therapy, Combination; Electrom | 2002 |
An artist's view of drug-induced hallucinosis.
Topics: Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2003 |
[Therapy for patients with early-stage Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combinati | 2003 |
[Treatment in Parkinson disease].
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; | 2004 |
Quality of life in Polish patients with long-lasting Parkinson's disease.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Depressive Disorder, Major; Dopa | 2004 |
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Topics: Amantadine; Antiparkinson Agents; Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; GTP Cycl | 2004 |
[Clinico-neurophysiologic and experimental study of the peculiarities of adamantan-sulphate treatment in Parkinson's disease].
Topics: Aged; Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Electromyography; Female; Humans | 2004 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combin | 2004 |
Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy | 2004 |
MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson's disease.
Topics: Action Potentials; Amantadine; Animals; Disease Models, Animal; Dizocilpine Maleate; Male; Neurons; | 2005 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Age | 2005 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug | 2005 |
[Functional brain activity in patients with Parkinson's disease during amantadin-sulfate therapy].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Brain; Electroencephalography; Female; Functional Lat | 2005 |
High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combin | 2005 |
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Hallucinations; | 2005 |
Drug-induced delusions of parasitosis during treatment of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delusions; Humans; Male; Parkinson Diseas | 2005 |
[Modern aproaches to the treatment of early stages of Parkinson disease].
Topics: Adult; Aged; Amantadine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Mal | 2005 |
Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Dominance, Cerebral; Dyskinesias; Electric Stimulatio | 2006 |
Amantadine-induced livedo reticularis: a report of two cases.
Topics: Aged; Amantadine; Antiparkinson Agents; Diagnosis, Differential; Female; Humans; Leg; Middle Aged; M | 2006 |
Initial pharmacotherapy in a population of veterans with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Dat | 2006 |
Association between amantadine and the onset of dementia in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Comorbidity; Dementia; Female; Humans; Male; Mental Status S | 2006 |
Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Deep | 2006 |
A reticular rash.
Topics: Aged; Amantadine; Antiparkinson Agents; Diagnosis, Differential; Drug Eruptions; Edema; Humans; Male | 2006 |
Features associated with the development of hallucinations in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Brain; Cholinergic Antagonists; Do | 2006 |
Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature.
Topics: Amantadine; Antiparkinson Agents; Cornea; Endothelium, Corneal; Humans; Male; Middle Aged; Parkinson | 2008 |
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs.
Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain | 2009 |
Amantadine may reverse punding in Parkinson's disease--observation in a patient.
Topics: Aged; Amantadine; Dopamine Agents; Drug Administration Schedule; Female; Humans; Parkinson Disease; | 2008 |
Amantadine-induced serotonin syndrome in a patient with renal failure.
Topics: Aged; Amantadine; Antiparkinson Agents; Comorbidity; Electroencephalography; Humans; Kidney Failure, | 2008 |
Medications for Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Brain; Cholinergic Antagonists; Dopamine; Dopamine Agents; Enzyme | 2007 |
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Cholinergic Antagonists; Dopami | 2008 |
[Drug therapy of parkinsonism].
Topics: Amantadine; Bromocriptine; Dopamine Antagonists; Humans; Levodopa; Neurotransmitter Agents; Parasymp | 1982 |
Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches.
Topics: Adrenergic beta-Antagonists; Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibito | 1984 |
[Therapeutic concept in Parkinson disease].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocri | 1983 |
Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combinat | 1983 |
Therapy of neurologic disorders in the elderly.
Topics: Aged; Amantadine; Anticoagulants; Brain Ischemia; Bromocriptine; Carbidopa; Dexamethasone; Drug Inte | 1984 |
The drug treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Therapy, Com | 1984 |
Binding of amantadine to red blood cells.
Topics: Adult; Aged; Amantadine; Binding Sites; Dose-Response Relationship, Drug; Erythrocytes; Female; Huma | 1984 |
Amantadine-dyazide interaction.
Topics: Amantadine; Ataxia; Creatine; Diuresis; Drug Combinations; Drug Synergism; Edema; Humans; Hydrochlor | 1983 |
[Treatment of Parkinson disease].
Topics: Amantadine; Dihydroxyphenylalanine; Drug Therapy, Combination; Ergot Alkaloids; Humans; Levodopa; Pa | 1982 |
Combined treatment in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 1983 |
[Parkinsonism].
Topics: Aged; Amantadine; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
Distribution of metabolism of the potential anti-parkinson drug memantine in the human.
Topics: Aged; Amantadine; Antiparkinson Agents; Brain Chemistry; Female; Humans; Memantine; Parkinson Diseas | 1980 |
Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease.
Topics: Amantadine; Amitriptyline; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Hyper | 1980 |
[Treatment of Parkinson's syndrome].
Topics: Amantadine; Extrapyramidal Tracts; Humans; Levodopa; Parkinson Disease; Sulfates | 1982 |
Initial treatment of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Administration Schedule; Drug Thera | 1982 |
The role of various forms of treatment in the management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergot | 1982 |
Parkinson's disease: new treatments.
Topics: Acetylcholine; Amantadine; Apomorphine; Bromocriptine; Carbidopa; Counseling; Dopamine; Humans; Levo | 1981 |
Amantadine-associated recurrence of psychosis.
Topics: Aged; Amantadine; Female; Humans; Parkinson Disease; Psychoses, Substance-Induced; Recurrence; Schiz | 1980 |
The posology of amantadine: a note of caution.
Topics: Amantadine; Humans; Parkinson Disease | 1980 |
[A study on mental symptoms developing during the treatment of Parkinson's disease (author's transl)].
Topics: Aged; Amantadine; Delusions; Drug Therapy, Combination; Female; Hallucinations; Humans; Hypertension | 1980 |
[Amantadine in the therapy of Parkinson syndromes].
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Stimulatio | 1980 |
[Initiation of treatment in Parkinson disease].
Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Mid | 1995 |
Confusion of drug names signalled.
Topics: Aged; Aged, 80 and over; Amantadine; Humans; Male; Medication Errors; Midodrine; Parkinson Disease | 1995 |
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Blood Platelets; Bromocriptine; Drug Therapy, Combination; Female; Humans; | 1995 |
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activ | 1994 |
Intracerebral co-grafting of Schwann's cells and fetal adrenal medulla in the treatment of Parkinson's disease.
Topics: Adrenal Medulla; Adult; Amantadine; Brain; Brain Tissue Transplantation; Female; Fetal Tissue Transp | 1994 |
Hereditary parkinsonism with multiple system degeneration: beneficial effect of anticholinergics, but not of levodopa.
Topics: Adult; Amantadine; Basal Ganglia; Carbidopa; Cerebellar Ataxia; Cholinergic Antagonists; Consanguini | 1994 |
Day-night variation of urine volume in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Bromocriptine; Circadian Rhythm; Female; Humans; Levodopa; Male; Middle Age | 1994 |
M-estimation in cross-over trials.
Topics: Amantadine; Asthma; Biometry; Clinical Trials as Topic; Forced Expiratory Volume; Humans; Least-Squa | 1994 |
Withdrawal-induced neuroleptic malignant syndrome.
Topics: Aged; Amantadine; Humans; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdra | 1994 |
Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride.
Topics: Amantadine; Cerebral Infarction; Corneal Diseases; Humans; Keratitis; Male; Middle Aged; Parkinson D | 1993 |
Amantadine withdrawal and neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Subs | 1993 |
Therapeutic brain concentration of the NMDA receptor antagonist amantadine.
Topics: Aged; Amantadine; Animals; Autopsy; Brain; Humans; Male; Microdialysis; Middle Aged; Parkinson Disea | 1995 |
Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts.
Topics: Adult; Amantadine; Antiparkinson Agents; Autopsy; Basal Ganglia; Brain Tissue Transplantation; Carbi | 1996 |
Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Uptake Inhi | 1996 |
Color vision in Parkinson's disease: missing influence of amantadine sulphate.
Topics: Aged; Amantadine; Color Perception; Female; Humans; Male; Middle Aged; Parkinson Disease; Visual Per | 1995 |
Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Ag | 1996 |
Breakthrough panic after amantadine treatment in a Parkinson's disease patient.
Topics: Adult; Amantadine; Humans; Male; Panic Disorder; Parkinson Disease; Recurrence | 1996 |
Amantadine-induced "vocal" myoclonus.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinatio | 1996 |
[Perioperative management of the patient with atypical Parkinson disease].
Topics: Amantadine; Anesthesia, General; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Intraopera | 1996 |
Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Corpus Striatum; Dextroamphetamine; Dopamine; Ion Channel | 1997 |
Current therapy of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Parkinson Disease; Pati | 1997 |
Triphasic waves in serotonin syndrome.
Topics: 1-Naphthylamine; Aged; Amantadine; Antiparkinson Agents; Brain Diseases; Carbidopa; Drug Combination | 1997 |
Amantadine in advanced Parkinson's disease: good use of an old drug.
Topics: Aged; Amantadine; Antiparkinson Agents; Humans; Male; Middle Aged; Parkinson Disease | 1997 |
Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1997 |
[Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; | 1997 |
Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Inappropriate | 1998 |
A frequency and correlation analysis of motor deficits in Parkinson patients.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; | 1998 |
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Topics: Acute Disease; Age of Onset; Aged; Amantadine; Delirium; Female; Humans; Male; Parkinson Disease; Su | 1998 |
[Dementia--Parkinson disease: role of antiglutamatergic drugs. Symposium: 4 April, Hamburg].
Topics: Amantadine; Antipsychotic Agents; Dementia; Humans; Levodopa; Movement Disorders; Parkinson Disease; | 1998 |
Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group.
Topics: Aged; Algorithms; Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Choline | 1998 |
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Dextromethorphan; Dextror | 1998 |
Possible new mechanism for the antiparkinsonian effect of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Do | 1999 |
More recent lessons from amantadine.
Topics: Amantadine; Humans; Parkinson Disease | 1999 |
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Topics: Amantadine; Delirium; Humans; Parkinson Disease; Substance Withdrawal Syndrome | 1999 |
Amantadine-induced peripheral neuropathy.
Topics: Amantadine; Antiparkinson Agents; Chronic Disease; Female; Humans; Leg; Middle Aged; Muscle Weakness | 1999 |
[Virus encephalitis with symptomatic Parkinson syndrome, diabetes insipidus and panhypopituitarism].
Topics: Aged; Amantadine; Anti-Inflammatory Agents; Antiparkinson Agents; Brain; Diabetes Insipidus; Encepha | 1999 |
Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cognition; Female; Humans; Injecti | 1999 |
[Incidence of amantadine-resistant influenza A (genotype Ser-31-Asn) in nursing homes in Niigata, Japan].
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Drug Resistance, Microbial; Genotype; Humans; In | 2000 |
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; | 2000 |
Freezing of gait in patients with advanced Parkinson's disease.
Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Femal | 2001 |
Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antiviral Agents; Cerebral Infarction; Dr | 2001 |
[L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
Topics: Amantadine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2001 |
A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system.
Topics: Aged; Amantadine; Binding, Competitive; Carbon Radioisotopes; Dopamine; Dopamine Agents; Dopamine An | 2001 |
Amantadine in Parkinson's disease: lymphocyte subsets and IL-2 secreting T cell precursor frequencies.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Female; Humans; Interleukin-2; Lymphocyte | 2001 |
Medical management of Parkinson's disease.
Topics: Amantadine; Cholinergic Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine | 2002 |
[Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Drug The | 2002 |
How to achieve maximum benefit for the patient with Parkinson's disease.
Topics: Aged; Amantadine; Carbidopa; Diagnosis, Differential; Histamine H1 Antagonists; Humans; Levodopa; Ne | 1976 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; | 1976 |
Parkinson's disease.
Topics: Amantadine; Antidepressive Agents; Carbidopa; Histamine H1 Antagonists; Humans; Levodopa; Parasympat | 1977 |
Update on drug treatment of Parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Histamine H1 Antagonists; Humans; Levodopa; | 1977 |
[Treatment of parkinson's syndrome. New developments].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents; Benzodiazepines; Carboxy-Lyases; Hum | 1978 |
[Parkinsonism].
Topics: Amantadine; Arteriosclerosis; Genes, Dominant; Guam; Histamine H1 Antagonists; Humans; Levodopa; Mid | 1978 |
Amantadine-induced heart-failure.
Topics: Aged; Amantadine; Heart Failure; Humans; Male; Parkinson Disease | 1977 |
Amantadine-induced heart-failure.
Topics: Aged; Amantadine; Arrhythmias, Cardiac; Coronary Disease; Heart Failure; Humans; Middle Aged; Parkin | 1977 |
A pseudohemipharetic form of Parkinson's disease.
Topics: Aged; Amantadine; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Functional | 1976 |
Drugs for Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Drug Evaluation; Humans; Levodopa; Monoamine Oxidas | 1978 |
Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
Topics: Aged; Amantadine; Benztropine; Biperiden; Delirium; Drug Eruptions; Female; Hallucinations; Humans; | 1975 |
[Circulatory disorders induced by amantidine].
Topics: Aged; Amantadine; Capillaries; Cardiovascular Diseases; Endoscopy; Female; Humans; Male; Microcircul | 1976 |
In practice. Parkinson's disease.
Topics: Amantadine; Basal Ganglia; Bromocriptine; Humans; Levodopa; Middle Aged; Movement; Parasympatholytic | 1979 |
Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Platelets; | 1975 |
Treating parkinsonism in the era of levodopa.
Topics: Amantadine; Antidepressive Agents; Anxiety; Depression; Histamine H1 Antagonists; Humans; Levodopa; | 1975 |
Diseases of the central nervous system. Pharmacological basis of treatment.
Topics: Amantadine; Analgesics, Opioid; Anticonvulsants; Blood-Brain Barrier; Central Nervous System Disease | 1975 |
Parkinson's disease.
Topics: Amantadine; Benztropine; Humans; Levodopa; Parkinson Disease; Procyclidine; Trihexyphenidyl | 1977 |
Increased appetite (bulimia) in Parkinson's disease.
Topics: Aged; Amantadine; Feeding and Eating Disorders; Female; Humans; Hunger; Levodopa; Male; Middle Aged; | 1977 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa | 1979 |
In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson.
Topics: Adamantane; Amantadine; Animals; Biological Transport; Bridged-Ring Compounds; Electric Stimulation; | 1979 |
[Combined use of metamizil and midantan in vascular parkinsonism].
Topics: Aged; Amantadine; Benactyzine; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Humans; | 1979 |
Electroretinographic changes in patients with parkinsonism treated with various classes of antiparkinsonian drugs.
Topics: Amantadine; Antiparkinson Agents; Electroretinography; Humans; Levodopa; Parasympatholytics; Parkins | 1979 |
Respiratory crisis in Parkinson's disease.
Topics: Aged; Amantadine; Crisis Intervention; Humans; Parkinson Disease; Respiratory Tract Infections | 1978 |
Amantadine-induced psychosis in a geriatric patient with renal disease.
Topics: Aged; Amantadine; Female; Humans; Kidney Failure, Chronic; Parkinson Disease; Psychoses, Substance-I | 1979 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physica | 1976 |
[Problematic long-term therapy of Parkinson's syndrome using amantadine salts].
Topics: Amantadine; Antidepressive Agents; Dihydroxyphenylalanine; Drug Therapy, Combination; Humans; Long-T | 1975 |
The shaking patient. Diagnosis and management of tremor.
Topics: Amantadine; Carbidopa; Cerebellar Diseases; Humans; Levodopa; Parkinson Disease; Propranolol; Tremor | 1977 |
[Treatment of parkinsonism].
Topics: Amantadine; Antiparkinson Agents; Carboxy-Lyases; Drug Combinations; Evaluation Studies as Topic; Hu | 1977 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; | 1977 |
Clinical and electromyographic examinations on the effect of hydrochloride (Viregyt-K) in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Male | 1977 |
Failure of L-dopa to relieve activated rigidity in Parkinson's disease.
Topics: Adult; Amantadine; Extrapyramidal Tracts; Hepatolenticular Degeneration; Humans; Levodopa; Male; Mid | 1977 |
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Topics: Aged; Amantadine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Methyld | 1976 |
[The effectiveness of amantadine (midantan) in the treatment of the parkinsonian syndrome].
Topics: Amantadine; Arteriosclerosis; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Di | 1976 |
[Treatment of parkinsonism].
Topics: Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; P | 1976 |
Removal of amantadine hydrochloride by dialysis in patients with renal insufficiency.
Topics: Aged; Amantadine; Humans; Kidney Failure, Chronic; Male; Parkinson Disease; Peritoneal Dialysis; Ren | 1976 |
Drug therapy of parkinsonism.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior; Dopa Decarboxylase; Drug Interac | 1976 |
[Interaction between L-dopa and other drugs].
Topics: Amantadine; Anti-Arrhythmia Agents; Apomorphine; Chlorpromazine; Drug Antagonism; Drug Interactions; | 1976 |
Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin.
Topics: Amantadine; Apomorphine; Growth Hormone; Humans; Levodopa; Parkinson Disease; Somatostatin | 1976 |
[Current drug treatment of parkinsonism].
Topics: Adult; Aged; Amantadine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; | 1976 |
[Amandatine hydrochloride (Symmetrel) in the treatment of parkinsonism].
Topics: Aged; Amantadine; Drug Evaluation; Drug Tolerance; Female; Humans; Male; Middle Aged; Parkinson Dise | 1976 |
[Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
Topics: Acetylcholine; Adult; Aged; Amantadine; Antiparkinson Agents; Cholinesterases; Drug Therapy, Combina | 1976 |
[Catecholamine excretion and treatment of parkinsonism with midantan].
Topics: Adult; Aged; Amantadine; Catecholamines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; Huma | 1976 |
[Trends in drug therapy: Amantadine - application of an anti-influenza drug as an antiparkinson agent].
Topics: Amantadine; Humans; Parkinson Disease | 1976 |
Levodopa-induced myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose | 1975 |
Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamantan).
Topics: Amantadine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Dopamine; Extrapyram | 1975 |
Letter: Electroconvulsive therapy in patients with parkinsonism.
Topics: Amantadine; Atropine; Depression; Diphenhydramine; Electroconvulsive Therapy; Female; Humans; Levodo | 1975 |
The mechanism of action of amantadine in Parkinsonism: a review.
Topics: Amantadine; Amines; Animals; Behavior, Animal; Body Temperature; Catecholamines; Central Nervous Sys | 1975 |
The treatment of parkinsonism.
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1975 |
[The antiparkinson activity of gludantan (preliminary report)].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Dihydroxyphenylalanine; Humans; Middle Aged; Parkinso | 1975 |
[Long-term therapy of parkinsonism using amantadine salts].
Topics: Amantadine; Humans; Parkinson Disease; Time Factors | 1976 |
[Treatment of parkinsonism].
Topics: Amantadine; Benztropine; Biperiden; Humans; Levodopa; Orphenadrine; Parkinson Disease; Procyclidine; | 1976 |
Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?
Topics: Acetylcholine; Amantadine; Animals; Corpus Striatum; Culture Techniques; Dose-Response Relationship, | 1992 |
Exteroceptive suppression of the masseter and temporalis muscles and parkinsonian rigidity.
Topics: Adult; Aged; Amantadine; Basal Ganglia; Bromocriptine; Electric Stimulation; Electromyography; Femal | 1991 |
Recovery of inter-block information in cross-over trials.
Topics: Amantadine; Analysis of Variance; Asthma; Clinical Trials as Topic; Data Interpretation, Statistical | 1991 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive The | 1991 |
Amantidine, the old anti-Parkinson medication, being useful in the fatigue syndrome that often accompanies multiple sclerosis.
Topics: Amantadine; Fatigue; Fatigue Syndrome, Chronic; Humans; Male; Middle Aged; Multiple Sclerosis; Parki | 1991 |
Bupropion and delirium.
Topics: Aged; Amantadine; Antidepressive Agents; Bupropion; Delirium; Depressive Disorder; Drug Therapy, Com | 1990 |
Hypersexuality with antiparkinsonian therapy.
Topics: Adult; Age Factors; Aged; Amantadine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; | 1989 |
Correlates of memory in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; | 1989 |
Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations.
Topics: Administration, Oral; Amantadine; Female; Humans; Injections, Intravenous; Male; Middle Aged; Parkin | 1989 |
Recent developments in the treatment of Parkinson's disease.
Topics: Aged; Aging; Amantadine; Diagnosis, Differential; Drug Administration Schedule; Dyskinesia, Drug-Ind | 1985 |
Comprehensive care of the patient with Parkinson's disease.
Topics: Aged; Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Muscle Rigidi | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder | 1986 |
Parkinson's disease in the elderly: current management strategies.
Topics: Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, C | 1987 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parki | 1988 |
[Intravenous and oral treatment with amantadine sulfate in Parkinson disease].
Topics: Administration, Oral; Amantadine; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neurops | 1988 |
Amantadine and motor fluctuations in chronic Parkinson's disease.
Topics: Adult; Aged; Amantadine; Chronic Disease; Female; Humans; Male; Middle Aged; Movement Disorders; Par | 1987 |
Long term amantadine treatment. The danger of withdrawal.
Topics: Aged; Amantadine; Female; Humans; Male; Parkinson Disease; Recurrence | 1987 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
Amantadine for levodopa resistant parkinsonism.
Topics: Aged; Amantadine; Drug Resistance; Female; Humans; Levodopa; Parkinson Disease | 1987 |
Parkinson's disease and pregnancy.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Amantadine; Female; Humans; Parkinson Disease; Preg | 1987 |
Pharmacotherapy: problems and practices.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parki | 1986 |
Drugs for parkinsonism.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combina | 1986 |
[Revision of the treatment strategy in Parkinson disease].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Humans; Levodopa; Monoamine Oxidase | 1986 |
Pharmacologic treatment of parkinsonian tremor.
Topics: Amantadine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tr | 1986 |
Treatment of major depression and Parkinson's disease with combined phenelzine and amantadine.
Topics: Aged; Amantadine; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Parkinson Disease; | 1985 |
[Restless legs syndrome in four parkinsonian patients treated with amantadine].
Topics: Aged; Amantadine; Female; Humans; Male; Middle Aged; Parkinson Disease; Restless Legs Syndrome | 1985 |
[Secondary effects of prolonged levodopa therapy in Parkinson's disease].
Topics: Age Factors; Aged; Amantadine; Antidepressive Agents, Tricyclic; Aromatic Amino Acid Decarboxylase I | 1985 |
Effects of lisuride on blink reflex habituation in Parkinson disease.
Topics: Adult; Aged; Amantadine; Blinking; Electrophysiology; Ergolines; Habituation, Psychophysiologic; Hum | 1985 |
Amantadine in Parkinsonism.
Topics: Aged; Amantadine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1970 |
Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.
Topics: Aged; Amantadine; Blood Vessels; Dihydroxyphenylalanine; Edema; Female; Gastrointestinal Diseases; H | 1971 |
[Syndrome involving the extrapyramidal motor systems and their drug treatment].
Topics: Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Dihydroxyphenylalanine; gamma-Aminobutyric | 1974 |
Amantadine in Parkinson's disease.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; Parkinson Disease | 1969 |
Amantadine in Parkinson's disease.
Topics: Aged; Amantadine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1970 |
Combined treatment of Parkinson's disease with amantadine and L-dopa.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1970 |
Mental symptoms in parkinsonian patients treated with L-dopa.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Humans; Male; Parkinson Disease | 1970 |
[Amantadine in the treatment of Parkinson's disease].
Topics: Amantadine; Drug Eruptions; Hallucinations; Humans; Parkinson Disease; Time Factors | 1972 |
Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Humans; Nerve Endings; Parasympatholyt | 1970 |
Mechanism of action of amantadine.
Topics: Aged; Amantadine; Dopamine; Female; Humans; Movement Disorders; Parkinson Disease; Synaptic Transmis | 1971 |
[Electrophysiological findings during treatment of the parkinsonian syndrome with amantadine].
Topics: Amantadine; Brain; Dihydroxyphenylalanine; Electrophysiology; Facial Nerve; Humans; Parkinson Diseas | 1971 |
[Effect of aminoadamantane sulfate on night sleep in Parkinson's disease].
Topics: Adult; Aged; Amantadine; Electroencephalography; Humans; Middle Aged; Motor Activity; Parkinson Dise | 1972 |
Habituation of blink reflexes in parkinsonian patients under levodopa and amantadine treatment.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Electromyography; Eye Movements; Female; Habituation, Psyc | 1972 |
L-Dopa therapy in Parkinson's disease.
Topics: Amantadine; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Parasympatholytics; Parkinson | 1970 |
Antagonism by amantadine of prochlorpemazine-induced catalepsy.
Topics: Amantadine; Animals; Barbiturates; Behavior, Animal; Catalepsy; Humans; Mice; Parkinson Disease; Pen | 1970 |
The relationship between the inhibition of dopamine uptake and the enhancement of amphetamine stereotypy.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Chlorpheniramine; Dopamine; Dopamine Antagonists | 1971 |
Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Parasympatholytics; Parkinson | 1972 |
Treatment of parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Phenothiazines; Propranolol | 1972 |
Clinical evaluation of amantadine therapy for parkinsonism and the side effects--in cases of thalamic surgery and L-dopa therapy.
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Drug Evaluation; Drug Synergism; Drug Therapy, Comb | 1974 |
[Use of the Soviet preparation midantan in the treatment of the Parkinsonian syndrome].
Topics: Adult; Aged; Amantadine; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle | 1974 |
[Treatment of parkinsonism with viregyt (amantadine)].
Topics: Adult; Aged; Amantadine; Drug Evaluation; Female; Humans; Male; Middle Aged; Parkinson Disease | 1974 |
[Effectiveness of a combination therapy in the Parkinson syndrome by amantadine hydrochloride and anticholinergic agents].
Topics: Adult; Aged; Amantadine; Drug Therapy, Combination; Humans; Middle Aged; Parasympatholytics; Parkins | 1974 |
[Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Hu | 1974 |
Parkinsonism as a falling sickness.
Topics: Age Factors; Aged; Amantadine; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders | 1974 |
Amantadine-HCl in the treatment of Parkinson's disease: a controlled trial.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Amantadine; Evaluation Studies as Top | 1972 |
Advances in the treatment of parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Parasympatholytics; Parkinson Disease | 1972 |
Amantadine and L-dopa.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1972 |
Effects of L-dopa on plasma growth hormones and insulin.
Topics: Administration, Oral; Amantadine; Blood Glucose; Dihydroxyphenylalanine; Growth Hormone; Humans; Inj | 1972 |
["Nil nocere." Side effects during treatment of Parkinson's disease with amantadine].
Topics: Aged; Amantadine; Cognition Disorders; Edema; Eyelids; Female; Fingers; Foot; Hand; Humans; Kidney; | 1972 |
[Amantadine therapy in parkinsonism].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1972 |
[The functional role of amantadine].
Topics: Amantadine; Animals; Central Nervous System; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Drug | 1972 |
[Surgical treatment of parkisonism in the light of the modern medical therapy].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Prognosis; Tremor | 1972 |
[Therapy of parkinsonism using L-dopa. I].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Hydrazines; Monoamine Oxidase Inhibitors; Parkinson Dise | 1972 |
Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects.
Topics: Adult; Aged; Amantadine; Catecholamines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; Hist | 1972 |
[Effects of L-dopa or amantadine treatment on the spindles of sleep in Parkinson's syndromes].
Topics: Amantadine; Brain; Dihydroxyphenylalanine; Electroencephalography; Humans; Parkinson Disease | 1972 |
[Drug therapy of Parkinson's diseases].
Topics: Amantadine; Dihydroxyphenylalanine; Gastrointestinal Diseases; Humans; Hypotension, Orthostatic; Men | 1972 |
Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
Topics: Amantadine; Amines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Histamine; Homovanillic Acid; Hum | 1972 |
Amantadine in Parkinson's disease. Review of more than two years' experience.
Topics: Aged; Amantadine; Ataxia; Constipation; Depression; Diarrhea; Dihydroxyphenylalanine; Drug Synergism | 1972 |
L-dopa for parkinsonism.
Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Follow-Up Studies; Hallucinations; Hum | 1973 |
[Amantadine therapy in parkinsonism].
Topics: Amantadine; Dihydroxyphenylalanine; Drug Synergism; Humans; Parasympatholytics; Parkinson Disease | 1973 |
Levodopa and related drugs.
Topics: Amantadine; Apomorphine; Dihydroxyphenylalanine; Humans; Hydrazines; Hypotension; Mental Disorders; | 1973 |
[Experience in the prolonged use of midantan (amantadine hydrochloride) in parkinsonism].
Topics: Administration, Oral; Adult; Aged; Amantadine; Chronic Disease; Electromyography; Epinephrine; Femal | 1973 |
Coloured Lilliputian hallucinations with amantadine.
Topics: Aged; Amantadine; Female; Hallucinations; Humans; Male; Parkinson Disease; Tremor; Visual Pathways | 1973 |
Interactions of L-dopa and amantadine in patients with Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Interactions; Evaluation Studies as Topic; Female; Homovani | 1973 |
Plasma growth hormone and insulin response to levodopa and amantadine.
Topics: Administration, Oral; Amantadine; Blood Glucose; Dihydroxyphenylalanine; Female; Growth Hormone; Hum | 1973 |
L-dopa level in plasma, primary condition for the kinetic effect.
Topics: Administration, Oral; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Biopharmaceuti | 1973 |
Permanent dementia in idiopathic Parkinsonism treated with levodopa.
Topics: Aged; Amantadine; Brain; Dihydroxyphenylalanine; Electroencephalography; Humans; Male; Parkinson Dis | 1973 |
Sporadic and familial parkinsonism and motor neuron disease.
Topics: Aged; Amantadine; Amyotrophic Lateral Sclerosis; Cerebellar Diseases; Corpus Striatum; Dihydroxyphen | 1973 |
Amantadine in the treatment of Parkinsonism and related diseases.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1973 |
[Combined therapy of parkinsonism using amantadine].
Topics: Amantadine; Dihydroxyphenylalanine; Drug Combinations; Humans; Parkinson Disease | 1973 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Blood-Brain Barrier; Dihydroxyphenylalanine; Humans; Hypotension; Parkinson Disease | 1973 |
Effect of amantadine on L-2-14C-dopa metabolism in parkinsonism.
Topics: Administration, Oral; Aged; Amantadine; Carbon Radioisotopes; Carboxylic Acids; Catecholamines; Chro | 1973 |
[Present-day treatment of parkinsonism in the aged].
Topics: Aged; Amantadine; Antiparkinson Agents; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combin | 1973 |
[Treatment with midantan of patients with parkinsonism].
Topics: Aged; Amantadine; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Parkinson Disease | 1973 |
New drugs-no. II: Amantadine.
Topics: Amantadine; Dose-Response Relationship, Drug; Parkinson Disease | 1973 |
[Therapy of akinetic crises].
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Paralysis; Parkinson Di | 1973 |
Amantadine enhancement of L-DOPA induced growth hormone stimulation.
Topics: Adult; Amantadine; Blood Glucose; Dihydroxyphenylalanine; Drug Synergism; Fatty Acids, Nonesterified | 1973 |
[Current medical treatment of Parkinsonian syndromes].
Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Combination | 1973 |
[Amantadine treatment in parkinsonism].
Topics: Administration, Oral; Amantadine; Anxiety; Hallucinations; Humans; Parkinson Disease; Sleep Wake Dis | 1973 |
[Accomplishment of the treatment and evaluation of treatment alternatives in parkinsonism].
Topics: Administration, Oral; Amantadine; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; | 1973 |
Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
Topics: Amantadine; Dihydroxyphenylalanine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson D | 1973 |
[Amantadine and the occurrence of livedo reticularis].
Topics: Amantadine; Female; Humans; Middle Aged; Parkinson Disease; Skin Manifestations; Vascular Diseases | 1974 |
[Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
Topics: Aged; Amantadine; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Humans; | 1974 |
[Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].
Topics: Amantadine; Anesthetics; Anti-Bacterial Agents; Antidepressive Agents; Antihypertensive Agents; Anti | 1974 |
Fotosensitization by Amantadine (Symmetrel).
Topics: Amantadine; Eczema; Female; Humans; Parkinson Disease; Photosensitivity Disorders; Skin Tests | 1974 |
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Cognition Disorders; Dihydroxyphenylalanine; Drug Therapy, Combination; Edema; Eye | 1974 |
Amantadine hydrochloride: alteration in peripheral circulation.
Topics: Aged; Amantadine; Aspartate Aminotransferases; Blood Cell Count; Blood Circulation; Dihydroxyphenyla | 1974 |
Polysynaptic spinal reflexes in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Drug Combinations; Electromyography; Female; Humans; Male; | 1974 |
The therapeutic possibilities of L-dopa and amantadine in Parkinsonian patients who have undergone bilateral thalamotomy.
Topics: Adolescent; Adult; Aged; Amantadine; Child; Dihydroxyphenylalanine; Electroencephalography; Female; | 1971 |
[Treatment of parkinsonian states with L-dopa].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1971 |
[Amantadine. Prolonged clinical trial in 50 parkinsonian patients].
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; Imipramine; Male; M | 1972 |
On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid.
Topics: Aged; Amantadine; Animals; Brain; Brain Chemistry; Female; Humans; Male; Middle Aged; Norepinephrine | 1972 |
Treatment for Parkinsonism, other than levodopa.
Topics: Amantadine; Humans; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1972 |
[Clinical trial of the therapeutic effect of Amantadine-HCL in Parkinson's Disease].
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; Male; Middle Aged; | 1972 |
Treatment of Parkinson's disease.
Topics: Amantadine; Counseling; Dihydroxyphenylalanine; Humans; Neurologic Manifestations; Parkinson Disease | 1972 |
[The treatment of Parkinson's disease with levodopa. Principles. Practical advice. Considerations].
Topics: Amantadine; Dihydroxyphenylalanine; Drug Combinations; Drug Interactions; Drug Tolerance; Female; Ho | 1972 |
[Combination of amantadine and levodopa in the treatment of Parkinson's disease. Indications. Results. Study of 58 cases].
Topics: Amantadine; Animals; Dihydroxyphenylalanine; Drug Synergism; Humans; Mice; Parkinson Disease | 1972 |
Levodopa and amantadine in the treatment of Parkinsonism.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Movement Disorders; Nau | 1972 |
Clinical manifestations of essential tremor.
Topics: Adult; Aged; Amantadine; Ataxia; Chlordiazepoxide; Dihydroxyphenylalanine; Female; Humans; Male; Mep | 1972 |
[Current treatment of Parkinsonism with amantadine hydrochloride].
Topics: Amantadine; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; Middle Aged; Parkinson Disease | 1972 |
[Long-time therapy of Parkinsonism with amantadine sulfate. Reply to L.W. Diehl: "Nil nocere. Adverse effects of amantadine therapy of parkinsonism"].
Topics: Amantadine; Chlorides; Humans; Intestinal Absorption; Lethal Dose 50; Parkinson Disease; Solubility; | 1972 |
[Amantadine therapy of Parkinson's syndrome. Comment on L.W. Diehl: "Nil nocere. Adverse effects of amantadine therapy of parkinsnism"].
Topics: Amantadine; Edema; Humans; Hypotension; Parkinson Disease; Psychoses, Substance-Induced; Sulfates | 1972 |
[Nil nocere. Adverse effects of amantadine therapy of parkinsonism. Summary to E.W. Fünfgeld: "Long-time therapy of parkinsonism with amantadine sulfate" and to G. Völler: "Amantadine therapy of parkinsonism"].
Topics: Amantadine; Humans; Intracranial Arteriosclerosis; Nephrotic Syndrome; Parkinson Disease; Psychoses, | 1972 |
[Amantadine in Parkinson's disease].
Topics: Adult; Aged; Amantadine; Female; Humans; Male; Middle Aged; Parkinson Disease; Time Factors | 1972 |
[Effects of amantadine therapy on sleep spindles in patients with parkinsonism and comparative analysis of L-dopa effects].
Topics: Adolescent; Adult; Amantadine; Desoxycorticosterone; Electroencephalography; Evaluation Studies as T | 1972 |
[Medical treatment of Parkinson's disease].
Topics: Amantadine; Carboxy-Lyases; Dihydroxyphenylalanine; Humans; Parasympatholytics; Parkinson Disease; P | 1972 |
[Treatment of Parkinson syndrome in general practice].
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Family Practice; Humans; Male; Parkinson Disease; Psychoth | 1972 |
L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
Topics: Aged; Amantadine; Chlorides; Depression; Dihydroxyphenylalanine; Drug Hypersensitivity; Female; Foll | 1971 |
[Amantadine in Parkinson's disease].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1971 |
Amantadine hydrochloride in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1971 |
[Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Drug Synergism; Electroencephalography; Electromyography; | 1971 |
[Amantadine in the treatment of Parkinson's disease. Results of one year].
Topics: Amantadine; Humans; Parkinson Disease | 1971 |
[Experimental and clinical data on the mechanism of action of amantadine and on its effectiveness in Parkinson's disease].
Topics: Acetylcholine; Aged; Amantadine; Amphetamine; Animals; Brain; Female; Guinea Pigs; Humans; Male; Mid | 1971 |
[Use of amantadine in the treatment of parkinsonism].
Topics: Amantadine; Humans; Parkinson Disease | 1971 |
[Preliminary results of the use of amantadine in parkinsonian syndromes].
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Diseas | 1971 |
[Combined treatment of parkinsonian syndromes with amantadine and gamma hydroxybutyric acid].
Topics: Amantadine; Humans; Hydroxybutyrates; Parkinson Disease | 1971 |
[Use of amantadine in parkinsonism].
Topics: Amantadine; Humans; Parkinson Disease | 1971 |
[Long-term effects of amantadine in striatal syndromes].
Topics: Adult; Aged; Amantadine; Humans; Intracranial Arteriosclerosis; Middle Aged; Movement Disorders; Par | 1971 |
[On the treatment of Parkinson's disease with intravenous administration of amantadine (77 cases)].
Topics: Administration, Oral; Amantadine; Humans; Injections, Intravenous; Parkinson Disease | 1971 |
[Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa].
Topics: Affective Symptoms; Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Psychotic Disorde | 1971 |
[6 months of treatment with amantadine and L-Dopa. Comparison in 2 groups of patients with parkinsonism].
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1971 |
[Data on the therapeutic action of amantadine in parkinsonian syndromes].
Topics: Aged; Amantadine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1971 |
[Effects of amantadine on the state of consciousness in diffuse cerebral psychosyndromes caused by vascular disorders].
Topics: Aged; Amantadine; Cerebrovascular Disorders; Female; Humans; Intracranial Arteriosclerosis; Male; Me | 1971 |
[On some effects of amantadine in muscle potentials in parkinsonism].
Topics: Amantadine; Evoked Potentials; Humans; Muscles; Parkinson Disease | 1971 |
[Action of amantadine on parkinsonian tremor].
Topics: Adult; Aged; Amantadine; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease; Promethazi | 1971 |
[Clinical results of the intravenous administration of amantadine in patients with parkinsonism].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Injections, Intravenous; Parkinson Disease | 1971 |
[Preliminary psychological findings during treatment of the parkinsonian syndrome with amantadine. Preliminary observations].
Topics: Amantadine; Anxiety; Depression; Dihydroxyphenylalanine; Emotions; Humans; Intelligence Tests; Menta | 1971 |
[Changes in the electroencephalogram during treatment with amantadine].
Topics: Amantadine; Brain; Chorea; Electroencephalography; Extrapyramidal Tracts; Humans; Movement Disorders | 1971 |
[Amantadine in the treatment of transitory hypokinesia in patients with parkinsonism during therapy with L-Dopa].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Psychomotor Disorders | 1971 |
[The addition of amantadine to prolonged treatment with L-Dopa. Considerations on 20 cases].
Topics: Adolescent; Adult; Aged; Amantadine; Child; Dihydroxyphenylalanine; Female; Humans; Male; Middle Age | 1971 |
[Amantadine and L-Dopa in the treatment of parkinsonian syndromes].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1971 |
[Therapeutic association of amantadine and L-Dopa in parkinsonism].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1971 |
[Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa].
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Diseas | 1971 |
[Amantadine hydrochloride in patients with parkinsonism in a Geriatric Rehabilitation Center].
Topics: Age Factors; Aged; Amantadine; Humans; Intracranial Arteriosclerosis; Middle Aged; Parkinson Disease | 1971 |
[Amantadine and L-Dopa in the treatment of parkinsonian syndromes and their implications for rehabilitation].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1971 |
[Prolonged treatment of Parkinson's disease with amantadine and L-Dopa].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Time Factors | 1971 |
[Modern therapeutics of Parkinson's disease].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1971 |
[Reticular livedo due to amantadine].
Topics: Adult; Amantadine; Female; Humans; Male; Parkinson Disease; Skin Diseases | 1971 |
[Conservative therapy in the Parkinson syndrome].
Topics: Amantadine; Antidepressive Agents; Dihydroxyphenylalanine; Humans; Imipramine; Injections, Intraveno | 1971 |
[Treatment of the Parkinson syndrome with amantadine].
Topics: Adult; Aged; Amantadine; Arteriosclerosis; Cognition Disorders; Dihydroxyphenylalanine; Drug Interac | 1971 |
Treatment of Parkinsonism with amantadine hydrochloride.
Topics: Amantadine; Humans; Parkinson Disease | 1971 |
Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease.
Topics: Amantadine; Animals; Catecholamines; Central Nervous System; Dopamine; Electrocoagulation; Hindlimb; | 1971 |
Blink reflex studies in patients with Parkinsonism before and during therapy.
Topics: Amantadine; Dihydroxyphenylalanine; Electric Stimulation; Electromyography; Eye Movements; Habituati | 1971 |
Non-resting tremor in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Humans; Male; Parkinson Disease; Propranolol; Tremor | 1971 |
[Current therapeutics of Parkinson's disease].
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease | 1971 |
Concurrent session: current trends in neurology and psychiatry.
Topics: Amantadine; Behavior Therapy; Dihydroxyphenylalanine; Epilepsy; Female; Humans; Male; Neurology; Par | 1971 |
Amantidine for relief of Parkinsonian tremor.
Topics: Amantadine; Antiviral Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; Tremor | 1971 |
The management of parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Combinations; Drug Synergism; Humans; Parkinson Disease | 1971 |
The medical management of Parkinson's disease before the introduction of L-dopa.
Topics: Amantadine; Antidepressive Agents; Humans; Parasympatholytics; Parkinson Disease; Physical Therapy M | 1971 |
[Advancement on the area of antiparkinsonism drugs].
Topics: Amantadine; Amino Acids; Brain; Dihydroxyphenylalanine; Humans; Parkinson Disease; Phenylalanine | 1969 |
A second report on Levodopa.
Topics: Amantadine; Arrhythmias, Cardiac; Cerebrovascular Disorders; Dihydroxyphenylalanine; Humans; Hypoten | 1969 |
Newer medical treatment in parkinsonism.
Topics: Adult; Aged; Amantadine; Dopamine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1970 |
Amantadine-dopamine interaction: possible mode of action in Parkinsonism.
Topics: Acetylcholine; Amantadine; Animals; Atropine; Dogs; Dopamine; Neurons; Parkinson Disease; Stimulatio | 1970 |
[Preliminary observations on the use of intravenous amantadine and of the association of oral amantadine with anticholinergic drugs and with levo-dopa in the treatment of Parkinson's disease].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parasympatholytics; Parkinson Disease | 1970 |
[The treatment of parkinsonism with amantadine].
Topics: Adult; Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parasympatholyti | 1970 |
The treatment of parkinsonism with L-Dopa and amantadine.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1970 |
[Amantadine for parkinsonism].
Topics: Amantadine; Humans; Middle Aged; Parkinson Disease; Statistics as Topic; Time Factors | 1970 |
Symmetrel in Parkinson' disease.
Topics: Adult; Aged; Amantadine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1970 |
Livedo reticularis in patients with parkinsonism receiving amantadine.
Topics: Amantadine; Female; Humans; Parkinson Disease; Telangiectasis | 1970 |
[Adamantylamine sulfate--a drug for treatment of Parkinson's disease with a new working principle].
Topics: Adult; Aged; Amantadine; Brain Stem; Humans; Middle Aged; Parkinson Disease; Sulfates | 1970 |
Specific therapy in Parkinson's disease.
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Hypotension, Orthostatic; Nausea; Parkinson Disease; Vom | 1970 |
Observations on the effect of amantadine hydrochloride in the treatment of Parkinsonism.
Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Muscle Tonu | 1970 |
Amantadine in the treatment of advanced Parkinsonism.
Topics: Amantadine; Chronic Disease; Humans; Parkinson Disease | 1970 |
L-dopa and amantadine for Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Synergism; Humans; Parkinson Disease | 1970 |
[Psychotic reactions in parkinsonian patients treated with amantadine].
Topics: Amantadine; Humans; Male; Middle Aged; Parkinson Disease | 1970 |
Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment.
Topics: Amantadine; Animals; Basal Ganglia; Dopamine; In Vitro Techniques; Nerve Endings; Parkinson Disease; | 1970 |
[Results of treatment with amantadine hydrochloride in Parkinson's syndrome using psychological test study methods. (Preliminary report)].
Topics: Administration, Oral; Aged; Amantadine; Capsules; Evaluation Studies as Topic; Female; Humans; Hydro | 1970 |
[Medical treatment of Parkinson's disease with amantadine hydrochloride. Preliminary note].
Topics: Adult; Aged; Amantadine; Female; Humans; Hydrochloric Acid; Male; Middle Aged; Parkinson Disease | 1970 |
[Current perspectives in the treatment of Parkinson's disease].
Topics: Age Factors; Amantadine; Dihydroxyphenylalanine; Humans; Injections, Intravenous; Parkinson Disease; | 1971 |
[Results of treatment with amantadine hydrochloride in Parkinson's syndrome using psychological test study methods. (Preliminary report)].
Topics: Administration, Oral; Aged; Amantadine; Capsules; Evaluation Studies as Topic; Female; Humans; Hydro | 1971 |
[Current therapeutic problems of the parkinson syndrome].
Topics: Amantadine; Dihydroxyphenylalanine; Humans; Parasympatholytics; Parkinson Disease | 1971 |
[Note on the treatment of parkinsonism with amantadine].
Topics: Amantadine; Humans; Parkinson Disease | 1971 |
Differentiation of tardive dyskinesias and drug-induced Parkinsonism.
Topics: Amantadine; Diagnosis, Differential; Dihydroxyphenylalanine; Humans; Hyperkinesis; Movement Disorder | 1971 |
Livedo reticularis during amantadine treatment.
Topics: Aged; Amantadine; Ankle; Blood Vessels; Edema; Epinephrine; Female; Humans; Isoproterenol; Male; Mid | 1971 |
Amantadine in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Drug Synergism; Humans; Male; Parkinson Disease | 1969 |
Parkinson's disease and amantadine hydrochloride.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Synergism; Humans; Parkinson Disease | 1969 |
New approaches in the treatment of parkinsonism.
Topics: Acetylcholine; Amantadine; Blood-Brain Barrier; Carboxy-Lyases; Dihydroxyphenylalanine; Dopamine; Fe | 1969 |